

273934

SEARCH REQ

Requester's Full Name: Cecilia Tingle Date: 9-30-08
 Alt. Title: 1634 Phone Number: 2-9981
 Location (Bldg./Room): RE-418 (Mailbox): 588 Results Format Preferred (circle): PAPER DIS

To ensure an efficient and quality search, please attach a copy of the cover sheet, index, and abstract of the sub-2, including:

Title of Invention: See Bib Data Sheet

Inventors (please provide full names):

Patent Priority Date:

Search Topics:

Please provide a concise summary of the invention, including the specific chemical compounds, processes, and/or systems, and a brief description of the invention's purpose and utility. Please also provide a list of keywords and synonyms used in the search. The summary should be no longer than 100 words.

For Sequence Search Only: Please include all pertinent information (e.g., title, abstract, or keyword) associated with the sequence search.

See claims attached. Please do structure research and identify names (e.g.) search. Display results to show identification of source, and R#*, compound name, structure of identified compounds. Search compounds of Formula III as indicated. See previous search.

Please call with any questions

STAMP USE ONLY

App. No.:	Type of Search:	Vendor and cost when applicable:
Search Store:	Full Text Search:	Yes <input type="checkbox"/> No <input type="checkbox"/>
Search Location:	Abstract Only:	Yes <input type="checkbox"/> No <input type="checkbox"/>
Search Date:	Index Only:	Yes <input type="checkbox"/> No <input type="checkbox"/>
Date Completed:	Operator:	Character: <input type="checkbox"/> Alphabet: <input type="checkbox"/> Symbol: <input type="checkbox"/>
Search Fee & Refund:	Refund:	Yes <input type="checkbox"/> No <input type="checkbox"/>
Call Date:	Index:	Yes <input type="checkbox"/> No <input type="checkbox"/>

=> file registry

FILE 'REGISTRY' ENTERED AT 15:49:38 ON 01 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file

10/576653

provided by InfoChem.

STRUCTURE FILE UPDATES: 30 SEP 2008 HIGHEST RN 1055704-91-0
DICTIONARY FILE UPDATES: 30 SEP 2008 HIGHEST RN 1055704-91-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> file zcaplus
FILE 'ZCAPLUS' ENTERED AT 15:49:41 ON 01 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS is
strictly prohibited.

FILE COVERS 1907 - 1 Oct 2008 VOL 149 ISS 14
FILE LAST UPDATED: 30 Sep 2008 (20080930/ED)

ZCaplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'ZCAPLUS' FILE

```
=> d stat que L33
L18      3072 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  CHENG W?/AU
L19      20 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  CO E?/AU
L20      19185 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  KIM M?/AU
L21      2503 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  KLEIN R?/AU
L22      3726 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  LE D?/AU
L23      6 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  TSUAKO A?/AU
L24      149 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  NUSS J?/AU
L25      9524 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  XU W?/AU
L26      5 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L18 AND (L19 OR L20 OR L21 OR
L22 OR L23 OR L24 OR L25)
L27      8 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L19 AND (L20 OR L21 OR L22 OR
```

10/576653

```

L28      16 SEA FILE=ZCAPLUS ABB=ON PLU=ON L20 AND (L21 OR L22 OR L23 OR
          L24 OR L25)
L29      5 SEA FILE=ZCAPLUS ABB=ON PLU=ON L21 AND (L22 OR L23 OR L24 OR
          L25)
L30      6 SEA FILE=ZCAPLUS ABB=ON PLU=ON L22 AND (L23 OR L24 OR L25)
L31      2 SEA FILE=ZCAPLUS ABB=ON PLU=ON L23 AND (L24 OR L25)
L32      13 SEA FILE=ZCAPLUS ABB=ON PLU=ON L24 AND L25
L33      24 SEA FILE=ZCAPLUS ABB=ON PLU=ON (L26 OR L27 OR L28 OR L29 OR
          L30 OR L31 OR L32)
```

=> file medline embase biosis wpix
FILE 'MEDLINE' ENTERED AT 15:49:50 ON 01 OCT 2008

FILE 'EMBASE' ENTERED AT 15:49:50 ON 01 OCT 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 15:49:50 ON 01 OCT 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'WPIX' ENTERED AT 15:49:50 ON 01 OCT 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

```

=> d stat que L34
L18      3072 SEA FILE=ZCAPLUS ABB=ON PLU=ON CHENG W?/AU
L19      20 SEA FILE=ZCAPLUS ABB=ON PLU=ON CO E?/AU
L20      19185 SEA FILE=ZCAPLUS ABB=ON PLU=ON KIM M?/AU
L21      2503 SEA FILE=ZCAPLUS ABB=ON PLU=ON KLEIN R?/AU
L22      3726 SEA FILE=ZCAPLUS ABB=ON PLU=ON LE D?/AU
L23      6 SEA FILE=ZCAPLUS ABB=ON PLU=ON TSUAKO A?/AU
L24      149 SEA FILE=ZCAPLUS ABB=ON PLU=ON NUSS J?/AU
L25      9524 SEA FILE=ZCAPLUS ABB=ON PLU=ON XU W?/AU
L26      5 SEA FILE=ZCAPLUS ABB=ON PLU=ON L18 AND (L19 OR L20 OR L21 OR
          L22 OR L23 OR L24 OR L25)
L27      8 SEA FILE=ZCAPLUS ABB=ON PLU=ON L19 AND (L20 OR L21 OR L22 OR
          L23 OR L24 OR L25)
L28      16 SEA FILE=ZCAPLUS ABB=ON PLU=ON L20 AND (L21 OR L22 OR L23 OR
          L24 OR L25)
L29      5 SEA FILE=ZCAPLUS ABB=ON PLU=ON L21 AND (L22 OR L23 OR L24 OR
          L25)
L30      6 SEA FILE=ZCAPLUS ABB=ON PLU=ON L22 AND (L23 OR L24 OR L25)
L31      2 SEA FILE=ZCAPLUS ABB=ON PLU=ON L23 AND (L24 OR L25)
L32      13 SEA FILE=ZCAPLUS ABB=ON PLU=ON L24 AND L25
L33      24 SEA FILE=ZCAPLUS ABB=ON PLU=ON (L26 OR L27 OR L28 OR L29 OR
          L30 OR L31 OR L32)
L34      23 SEA L33
```

=> dup rem L33 L34
FILE 'ZCAPLUS' ENTERED AT 15:50:05 ON 01 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 15:50:05 ON 01 OCT 2008

FILE 'BIOSIS' ENTERED AT 15:50:05 ON 01 OCT 2008
Copyright (c) 2008 The Thomson Corporation

10/576653

FILE 'WPIX' ENTERED AT 15:50:05 ON 01 OCT 2008
 COPYRIGHT (C) 2008 THOMSON REUTERS
 PROCESSING COMPLETED FOR L33
 PROCESSING COMPLETED FOR L34
 L35 31 DUP REM L33 L34 (16 DUPLICATES REMOVED)

ANSWERS '1-24' FROM FILE ZCAPLUS
 ANSWER '25' FROM FILE MEDLINE
 ANSWER '26' FROM FILE BIOSIS
 ANSWERS '27-31' FROM FILE WPIX

=> d ibib abs L35 1-24; d iall L35 25-31

L35 ANSWER 1 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2007:464459 ZCAPLUS Full-text

DOCUMENT NUMBER: 146:462283

TITLE: Preparation of pyrimidinones as casein kinase II (CK2) modulators for the treatment of cancer

INVENTOR(S): Rice, Kenneth D.; Anand, Neel Kumar; Arcalas, Arlyn; Blazey, Charles M.; Bussenius, Joerg; Chan, Wai Ki Vicky; Du, Hongwang; Epshteyn, Sergey; Ibrahim, Mohamed Abdulkader; Kearney, Patrick; Kennedy, Abigail R.; Kim, Moon Hwan; Manalo, Jean-Claire Limun; Peto, Csaba J.; Tsang, Tsze H.; Tshako, Amy Lew; Zhou, Peiwen

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 83pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007048065	A2	20070426	WO 2006-US41505	20061023
WO 2007048065	A3	20070628		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RM:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BG, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2006304874	A1	20070426	AU 2006-304874	20061023
CA 2626789	A1	20070426	CA 2006-2626789	20061023
EP 1948617	A2	20080730	EP 2006-826578	20061023
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
PRIORITY APPLN. INFO.:			US 2005-729348P	P 20051021
			WO 2006-US41505	W 20061023

OTHER SOURCE(S): MARPAT 146:462283

GI



AB Compound I [wherein X = O or S; R1, R2 = (un)substituted aryl, arylamino, pyridinyl, etc., with limitations] or pharmaceutically acceptable salts thereof were prepared as casein kinase II (CK2) modulators. For instance, successive O-protection of 1-(4-hydroxy-3-methylphenyl)ethanone with BnBr, condensation with Me 2-(2-methoxyethoxy)benzoate, cyclocondensation of the resultant 1,3-dicarbonyl with urea, and debenzoylation with TFA led to pyrimidinone II as a hydrochloride salt. Representative examples I showed CK2 inhibitory activity with IC50 values of less than 5000 nM. The invented compds. and their pharmaceutical compns. are useful for the treatment of diseases that involve CK2, such as cancer.

L35 ANSWER 2 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2007:438699 ZCAPLUS [Full-text](#)

DOCUMENT NUMBER: 146:441822

TITLE: 2-Amino-3-sulfonylaminoquinoxaline derivatives as phosphatidylinositol 3-kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer

INVENTOR(S): Bajjalieh, William; Bannen, Lynne Canne; Brown, S. David; Kearney, Patrick; Mac, Morrison; Marlowe, Charles K.; Nuss, John M.; Tesfai, Zerom; Wang, Yong; Xu, Wei

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 296pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007044729	A2	20070419	WO 2006-US39574	20061009
WO 2007044729	A3	20070809		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,			

KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA


AU 2006302179	A1	20070419	AU 2006-302179	20061009
CA 2623768	A1	20070419	CA 2006-2623768	20061009
EP 1931645	A2	20080618	EP 2006-836252	20061009

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

IN 2008KN01170	A	20080822	IN 2008-KN1170	20080319
MX 200804402	A	20080421	MX 2008-4402	20080402
KR 2008068651	A	20080723	KR 2008-708373	20080407

PRIORITY APPLN. INFO.:
 US 2005-724570P P 20051007
 US 2006-812690P P 20060608
 WO 2006-US39574 W 20061009

OTHER SOURCE(S): MARPAT 146:441822
 GI



AB The invention comprises 2-amino-3-sulfonylaminoquinoxaline derivs. of formula I, as inhibitors of phosphatidylinositol 3-kinase (PI3K), which is associated with a number of malignancies such as ovarian cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, and glioblastomas, among others. Accordingly, the compds. of formula I are useful for treating, preventing, and/or inhibiting these diseases. Compds. of formula I wherein W1, W2, W3 and W4 are CR6; or one or two of W1, W2, W3 and W4 are independently N; R6 is H, (halo)alkyl, NO2, (halo)alkoxy, halo, OH, CN, NH2, and (mono/di)alkylamino; R1, R4 and R5 are independently H, (halo)alkyl, (halo)alkenyl, halo, OH, (halo)alkoxy, alkenyloxy, NO2, amino, and (mono/di)alkylamino, etc.; R2 is H and alkyl; R3 is H and halo; B is (un)substituted Ph and (un)substituted heteroaryl; and their pharmaceutically acceptable salts and solvates thereof, are claimed. Example compound II was prepared by amidation of 6-chloropyridine-3-sulfonyl chloride, the resulting 6-chloropyridine-3-sulfonamide underwent arylation with 2,3-dichloroquinoxaline to give 6-chloro-N-(3-chloroquinoxalin-2-yl)pyridine-3-sulfonamide, which underwent amination with 3,5-dimethoxyaniline to give compound II. All the invention compds. were evaluated for their PI3K inhibitory activity (data given). Examples of the pharmaceutical compns. are also given.

L35 ANSWER 3 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2006:1066309 ZCAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:418960

TITLE: Preparation of quinolines as modulators of c-Met, KDR, c-Kit, flt-3, and flt-4 kinases.

INVENTOR(S): Forsyth, Timothy Patrick; Mac, Morrison B.; Leahy, James William; Nuss, John M.; Xu, Wei


PATENT ASSIGNEE(S): Exelixis, Inc., USA

10/576653

SOURCE: PCT Int. Appl., 147pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006108059	A1	20061012	WO 2006-US12709	20060406
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006231646	A2	20061012	AU 2006-231646	20060406
AU 2006231646	A1	20061012		
CA 2603748	A1	20061012	CA 2006-2603748	20060406
EP 1874759	A1	20080109	EP 2006-749361	20060406
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008537748	T	20080925	JP 2008-505496	20060406
US 20080161305	A1	20080703	US 2007-910720	20071121
PRIORITY APPLN. INFO.:			US 2005-669207P	P 20050406
			WO 2006-US12709	W 20060406

OTHER SOURCE(S): MARPAT 145:418960
 GI





AB Title compds. [I; R1 = H, halo, OR3, NO2, NH2, NR3R4; R3 = H, R4; R4 = (substituted) alkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; NR3R4 = 5-7 membered (substituted) heterocyclyl; Z = S, SO, SO2, O, NR5; R5 = H, (substituted) alkyl; Ar = (substituted) Ph, pyridyl, pyridazinyl, benzothienyl, benzoxazolyl, benzimidazolyl; D = O, S, SO, SO2, NR15; R15 = M1M2; M1 = null, CSNR13, CO, SO2, SO2NR13, etc.; M2 = H, alkyl, alkoxy, (substituted) cyclyl(alkyl)carbonyl, cyclyl(alkyl), etc.; R50 = R3, specified (substituted) (bicyclic) ring; with provisos], were prepared Thus, N-[3-fluoro-4-[[6-(methoxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl]oxy]phenyl]-N'-[2-(4-fluorophenyl)ethyl]ethanediamide (preparation given) inhibited c-Met, KDR, c-Kit, flt-3, and flt-4 kinases with IC50 <50 nM.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/576653

L35 ANSWER 4 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 4
 ACCESSION NUMBER: 2006:655708 ZCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 145:124611
 TITLE: Preparation of [1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Akt-1 and Akt-2) for the treatment of immunological, inflammatory and proliferative diseases
 INVENTOR(S): Rice, Ken; Co, Erick Wang; Kim, Moon Hwan; Bannen, Lynn Canne; Bussenius, Joerg; Lee, Donna; Tsubako, Amy Lew; Nuss, John; Wang, Yong; Xu, Wei; Klein, Rhett Ronald
 PATENT ASSIGNEE(S): Exelixis, Inc., USA
 SOURCE: PCT Int. Appl., 126 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006071819	A1	20060706	WO 2005-US46938	20051227
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2005322085	A1	20060706	AU 2005-322085	20051227
CA 2590961	A1	20060706	CA 2005-2590961	20051227
EP 1848719	A1	20071031	EP 2005-855490	20051227
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
JP 2008525526	T	20080717	JP 2007-549530	20051227
US 20080188482	A1	20080807	US 2007-722291	20071010
PRIORITY APPLN. INFO.:			US 2004-640200P	P 20041228
			WO 2005-US46938	W 20051227
OTHER SOURCE(S):	MARPAT 145:124611			
GI				



AB The title compds. I [R1 = H, halo, CN, aryl, etc.; R2 = H, NH2, SH, OH or alkyl; R3-R6 = H, oxo, alkyl, alkoxy, etc.; L = alkylene, alkenylene, C(O), etc.; Q1 = N, CR13 (wherein R13 = H or C(O)NR12(CH2)nNR10R11); Q2 = a bond, CR14, O or N (R14 = H, OH, alkyl, etc.); n = 1-4; W = alkyl, NR10R11, aryl, cycloalkyl, etc.; or V, Q2, L and W together form aryl ring, heteroaryl ring, substituted with aryl or heteroaryl; with provisos], useful for inhibition of kinases, more specifically p70S6 kinases, and more preferably p70S6, Akt-1 and Akt-2 kinases, were prepared E.g., a multi-step synthesis of II, starting from N-Boc-4-(4-chlorobenzoyl)piperidine and 2-(diethylamino)ethylamine, was given. Compds. I were tested against p70S6K, Akt-1 and Akt-2 (IC50 values were given for representative compds. I). The invention provides compds. for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism Compds. I inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compns. which contain these compds., and methods of using them to treat kinase-dependent diseases and conditions.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 5 OF 31 ZCAPLUS COPYRIGHT 2008 ACS ON STN DUPLICATE 5

ACCESSION NUMBER: 2006:119818 ZCAPLUS Full-text

DOCUMENT NUMBER: 144:212795

TITLE: Preparation of fused-ring pyrimidine-containing C-met modulators and method of use against proliferative disorders

INVENTOR(S): Bannen, Lynne Canne; Chan, Diva Sze-Ming; Dalrymple, Lisa Esther; Jammalamadaka, Vasu; Khoury, Richard George; Leahy, James William; Mac, Morrison B.; Mann, Grace; Mann, Larry W.; Nuss, John M.; Parks, Jason Jevious; Wang, Yong; Xu, Wei

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 104 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006014325	A2	20060209	WO 2005-US23364	20050701

WO 2006014325 A3 20070301

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU 2005270068 A1 20060209 AU 2005-270068 20050701
 CA 2572331 A1 20060209 CA 2005-2572331 20050701
 EP 1773826 A2 20070418 EP 2005-763620 20050701


R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU

JP 2008505181 T 20080221 JP 2007-520386 20050701
 US 20070179130 A1 20070802 US 2006-571140 20061221

PRIORITY APPLN. INFO.: US 2004-584977P P 20040702
 WO 2005-US23364 W 20050701

OTHER SOURCE(S): MARPAT 144:212795

GI



AB The present invention provides fused-ring pyrimidine-containing compds. (shown as I; variables defined below; e.g. N-(4-fluorophenyl)-N'-[3-fluoro-4-[(7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]phenyl]propanediamide (shown as II)) for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides appropriately functionalized 5,6-fused bicyclics that inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, and flt-3, signal transduction pathways related to the changes in cellular activities as mentioned above, compds. which contain these compds., and methods of using them to treat kinase-dependent diseases and conditions. For I: Each of J1, J2, and J3 = :N-

, :C(R1)-, -N(R1)-, -O- and -S(O)0-2-; R2 = -H, halo, -OR20, -S(O)0-2R20, -NO2, -N(R20)R20, and (un)substituted C1-6alkyl; J4 = :N-, :C(H)-, and :C(CN)-; Ar is either a five- or six-membered arylene or a five- or six-membered heteroarylene containing 1-3 heteroatoms; each R3 = -H, halo, trihalomethyl, -CN, -NO2, -OR20, -N(R20)R20, -S(O)0-2R20, -SO2N(R20)R20, -CO2R20, -C(O)N(R20)R20, -N(R20)SO2R20, -N(R20)C(O)R20, -NCO2R20, -C(O)R20, (un)substituted C1-6alkyl, (un)substituted aryl, (un)substituted aryl C1-6alkyl, (un)substituted heterocyclyl, (un)substituted heterocyclyl C1-6alkyl, et al.; Z = -S(O)0-2-, -O-, and -NR4; addnl. details are given in the claims. Although the methods of preparation are not claimed, preps. and/or characterization data for .apprx.30 examples of I and intermediates are included. For example, II was prepared (21 %) by amide formation from [3-fluoro-4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl]amine (preparation described) and 2-(4-fluorophenylcarbamoyl)acetic acid in DMF in the presence of HATU and Et3N. Semiquant. IC50 values for inhibition of c-Met, KDR and flt-3 kinases are tabulated for 12 examples of I.

L35 ANSWER 6 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 6

ACCESSION NUMBER: 2005:1314205 ZCAPLUS Full-text

DOCUMENT NUMBER: 144:51610

TITLE: Preparation and structure activity of pyrazolo-pyrimidine derivatives as antitumor agents and kinase modulators

INVENTOR(S): Anand, Neel K.; Blazey, Charles M.; Bowles, Owen Joseph; Bussenius, Joerg; Canne Bannen, Lynne; Chan, Diva Sze-Ming; Chen, Baili; Co, Erick Wang; Costanzo, Simona; Defina, Steven Charles; Dubenko, Larisa; Franzini, Maurizio; Huang, Ping; Jammalamadaka, Vasu; Khoury, Richard George; Kim, Moon Hwan; Klein, Rhett Ronald; Le, Donna Tra; Mac, Morrison B.; Nuss, John M.; Parks, Jason Jevious; Rice, Kenneth D.; Tsang, Tsze H.; Tshako, Amy Lew; Wang, Yong; Xu, Wei

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 211 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005117909	A2	20051215	WO 2005-US13860	20050422
WO 2005117909	A3	20060427		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005249380	A1	20051215	AU 2005-249380	20050422
CA 2563699	A1	20051215	CA 2005-2563699	20050422



AB Pyrazolo-pyrimidine derivs. I, wherein X1 is N, CR2, X2 is N, CR3; X3 is N, CR4, but when X2 is N then X3 is CR4; R is H, halogen, tri-halomethyl, substituted nitrogen, substituted sulfur, sulfonyl, sulfonamide, carboxylate, amide, substituted oxygen, acyl, alkyl, aryl, heterocycle, heterocycloalkyl, arylalkyl R1-R13 are independently H, halogen, tri-halomethyl, CN, NO2, substituted nitrogen, substituted sulfur, sulfonyl, sulfonamide, carboxylate, amide, substituted oxygen, acyl, alkyl, aryl, heterocycle, heterocycloalkyl, arylalkyl; Q is (C)nR11R12; n is 0-1 are prepared as kinase modulators. Combination chemotherapy and structure activity of title compds. are reported. The compds. modulate protein kinase enzymic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compds. of the invention inhibit, regulate and/or modulate kinases, particularly p70S6 and/or AKT kinases. Methods of using and preparing the compds., and pharmaceutical compns. thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention. Thus, 3-(4-azetidin-3-ylidene-methyl)-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine was prepared and tested in vitro as kinase modulator (IC50 > 1000 nM).

L35 ANSWER 7 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 7
ACCESSION NUMBER: 2005:395446 ZCAPLUS Full-text
DOCUMENT NUMBER: 142:406543
TITLE: TAO kinase inhibitors for pharmaceutical use and for screening for kinase modulators
INVENTOR(S): Xu, Wei; Zheng, Wentao; Baly, Deborah Lynn; Galan, Adam Antoni; Ibrahim, Mohamed Abdulkader; Jaeger, Christopher; Kearney, Patrick; Leahy, James William; Lewis, Gary Lee; McMillan, Kirk; Noguchi, Robin Tammie; Nuss, John M.; Parks, Jason Jevous;

PATENT ASSIGNEE(S): Schnepp, Kevin Luke; Shi, Xian; Williams, Matthew Alan
 SOURCE: Exelixis, Inc., USA
 PCT Int. Appl., 109 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040355	A2	20050506	WO 2004-US35469	20041022
WO 2005040355	A3	20050804		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004283313	A1	20050506	AU 2004-283313	20041022
CA 2542064	A1	20050506	CA 2004-2542064	20041022
EP 1678121	A2	20060712	EP 2004-796442	20041022
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007527412	T	20070927	JP 2006-536928	20041022
US 20070208166	A1	20070906	US 2006-576932	20061019
PRIORITY APPLN. INFO.:			US 2003-514377P	P 20031024
			WO 2004-US35469	W 20041022

OTHER SOURCE(S): MARPAT 142:406543

AB The invention provides compds. and methods for inhibition of kinases, such as those of the TAO family, more specifically KIAA1361, TAO, and JIK kinases. The invention provides compds. for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, and chemoinvasion. Compds. of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compds. which contain these compds., and methods of using them to treat kinase-dependent diseases and conditions. Thus, N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,d][1,4]diazepine-3-carboxamide was synthesized. This compound exhibited an IC50 with JIK kinase of <50 nM and an IC50 with TAO kinase of between 50 and 500 nM.



L35 ANSWER 8 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 8
 ACCESSION NUMBER: 2005:395042 ZCAPLUS Full-text
 DOCUMENT NUMBER: 142:447414
 TITLE: P7056 kinase modulators and method of use
 INVENTOR(S): Cheng, Wei; Co, Erick Wang; Kim, Moon Hwan; Klein, Rhett Ronald; Le Donna, T.; Lew, Amy; Nuss, John M.; Xu, Wei
 PATENT ASSIGNEE(S): Exelixis, Inc., USA
 SOURCE: PCT Int. Appl., 165 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent

10/576653

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039506	A2	20050506	WO 2004-US35470	20041022
WO 2005039506	A3	20060119		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004283751	A1	20050506	AU 2004-283751	20041022
CA 2541989	A1	20050506	CA 2004-2541989	20041022
EP 1678168	A2	20060712	EP 2004-796443	20041022
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007527413	T	20070927	JP 2006-536929	20041022
US 20070208020	A1	20070906	US 2006-576653	20061116
PRIORITY APPLN. INFO.:			US 2003-514432P	P 20031024
			US 2004-551429P	P 20040308
			WO 2004-US35470	W 20041022

OTHER SOURCE(S): CASREACT 142:447414; MARPAT 142:447414
 GI



AB Peptide derivs. I [E = C(R2)-substituted pyridine, pyridazine, pyrimidine, or 1,3,5-triazine; B = (R1)n; R1, R2 = H, halo, trihalomethyl, CN, NO2, aminoalkyl, carboxyalkyl, (un)substituted alky, alkenyl, alkynyl, aryl, heterocyclyl, heterocyclyl, heterocyclylalkyl, arylalkyl, etc.; X, Y = CO, O, (un)substituted amine, (un)substituted imine, SO; X and Y can combine to form either C(R3):C(R3), or C.tplbond.C; when X = O, (un)substituted amine, or (un)substituted imine, Y cannot be CH(R3); R3 = (un)substituted Ph, naphthyl, cyclohexyl, dihydronaphthyl, five- to six-membered heteroaryl; Z = O, S, double bond to an atom of B; A = single bond, NH, (un)substituted aminoalkyl,

aminoaryl, aminoaryllalkyl, aminoheterocyclyl, aminoheterocyclylalkyl; J = (un)substituted five- to ten-membered aryl or heteroaryl, etc.; n = 0-5) or pharmaceutically acceptable salts, hydrates, or prodrugs were prepared as p70S6 kinase signal transduction inhibitors and cellular activities modulators for treating kinase-dependent diseases and conditions. Thus, compound II was prepared by coupling of 2-amino-4,6-di-chloro-5-formylpyrimidine with 2-amino-N-(3- trifluoromethylphenyl)acetamide in 43% yield and showed IC50 < 50 nM in p70S6 kinase activity assay.

L35 ANSWER 9 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 9

ACCESSION NUMBER: 2005:300201 ZCAPLUS [Full-text](#)

DOCUMENT NUMBER: 142:3/3856

TITLE: Preparation of quinolines and quinazolines as inhibitors of c-Met and other tyrosine kinases and therapeutic uses against proliferative diseases

INVENTOR(S): Bannen, Lynne Canne; Chan, Diva Sze-ming; Chen, Jeff; Dairymple, Lisa Esther; Forsyth, Timothy Patrick; Huynh, Tai Phat; Jammalamadaka, Vasu; Khoury, Richard George; Leahy, James William; Mac, Morrison B.; Mann, Grace; Mann, Larry W.; Nuss, John M.; Parks, Jason Jevious; Takeuchi, Craig Stacy; Wang, Yong; Xu, Wei

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCI Int. Appl., 428 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030140	A2	20050407	WO 2004-US31523	20040924
WO 2005030140	A3	20050519		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004275842	A1	20050407	AU 2004-275842	20040924
CA 2537812	A1	20050407	CA 2004-2537812	20040924
EP 1673085	A2	20060628	EP 2004-789057	20040924
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007506777	T	20070322	JP 2006-528265	20040924
US 20070054928	A1	20070308	US 2006-586751	20061026
US 20070225307	A1	20070927	US 2007-753462	20070524
US 20070244116	A1	20071018	US 2007-753503	20070524
PRIORITY APPLN. INFO.:			US 2003-506181P	P 20030926
			US 2004-535377P	P 20040109
			US 2004-577384P	P 20040604
			WO 2004-US31523	W 20040924
			US 2006-573336	B1 20060918
			US 2006-586751	A1 20061026





AB The present invention provides compds. (shown as I; variables defined below; e.g. N-[4-[[[7-[[2-(diethylamino)ethyl]oxy]-6-(methoxy)quinolin-4-yl]oxy]-3-fluorophenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (shown as II)) for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptors, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compns. which contain these compds., and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compds. as mentioned above, and compns. which contain these compds. For I: R¹ = H, halogen, OR³, NO², NH², NR³R⁴, and (un)substituted lower alkyl; A¹ = :N-, :C(H)-, and :C(CN)-; Z = -S(O)O-2-, -O-, and -NR⁵-; Ar is aryl or heteroaryl; D = -O-, -S(O)O-2-, and -NR¹⁵-; R⁵O = R³ or bicyclic radical; addnl. details are given in the claims. Methods of preparation are claimed and .apprx.80 example preps. of I and intermediates are included. For example, II was prepared (34 %) from 2-(diethylamino)ethanol and cyclopropane-1,1-dicarboxylic acid N-[3-fluoro-4-[[7-hydroxy-6-methoxyquinolin-4-yl]oxy]phenyl]amide N-(4-fluorophenyl)amide, which was prepared (89 %) by deprotection of cyclopropane-1,1-dicarboxylic acid N-[4-[[7-benzyloxy-6-methoxyquinolin-4-yl]oxy]-3-fluorophenyl]amide N-(4-fluorophenyl)amide, which was prepared (48 %) from trifluoromethanesulfonic acid 7-benzyloxy-6-methoxyquinolin-4-yl ester and cyclopropane-1,1-dicarboxylic acid N-(3-fluoro-4-hydroxyphenyl)amide N-(4-fluorophenyl)amide, which was prepared (85 %) by deprotection of cyclopropane-1,1-dicarboxylic acid N-(4-benzyloxy-3-fluorophenyl)amide N-(4-fluorophenyl)amide, which was prepared (98 %) from (4-benzyloxy-3-fluorophenyl)amine and 1-(4-fluorophenyl)carbamoyl)cyclopropanecarboxylic acid; addnl. details are given in the examples.

10/576653

L35 ANSWER 10 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 10
 ACCESSION NUMBER: 2005:216619 ZCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 142:297864
 TITLE: Preparation of aniline derivatives and related compounds as c-kit modulators
 INVENTOR(S): Cheng, Wei; Co, Erick Wang; Kim, Moon Hwan; Klein, Rhett Ronald; Le Donna, T.; Lew, Amy; Nuss, John M.; Xu, Wei; Bajjalieh, William
 PATENT ASSIGNEE(S): Exelixis, Inc., USA
 SOURCE: PCT Int. Appl., 169 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020921	A2	20050310	WO 2004-US28001	20040827
WO 2005020921	A3	20051006		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004268621	A1	20050310	AU 2004-268621	20040827
CA 2536954	A1	20050310	CA 2004-2536954	20040827
EP 1663204	A2	20060607	EP 2004-782473	20040827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007504160	T	20070301	JP 2006-524905	20040827
US 20080096892	A1	20080424	US 2007-569873	20070904
PRIORITY APPLN. INFO.:			US 2003-499224P	P 20030829
			WO 2004-US28001	W 20040827
OTHER SOURCE(S):			CASREACT 142:297864; MARPAT 142:297864	

GI



AB Compds. I [wherein ring A is a five- to fourteen-membered heteroaryl; R1, R2 and R3 are H, halo, trihalomethyl, cyano, nitro, etc.; L1 is a single bond, (un)substituted alkylene, O, CH2O, etc.; ring B is five- to ten-membered aryl or heterocyclyl; ring C is five- to ten-membered (hetero)aryl; L2 is alkylene, alkylidene, alkylidyne, etc.; with some limitations and exclusions, and pharmaceutically acceptable salts, hydrates or prodrugs thereof], as exemplified by carbonyl compds. of anilines, were prepared as c-Kit kinase modulators. For example, 3-aminophenoxyacetic acid, which was obtained from the corresponding nitro compound in 76% yield via catalytic hydrogenation, was treated with HC(OEt)3 and NaN3 in AcOH followed by NaNO2/HCl to give a tetrazole in 61% yield. This acid was coupled with 5-amino-2-chlorobenzotrifluoride in the presence of HATU to afford acetamide II in 46% yield, which showed inhibition against c-Kit kinase with a IC50 of < 50 nM. Therefore, I and pharmaceutical compns. thereof are useful for modulating c-Kit kinase activity and for treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities.

L35 ANSWER 11 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 11

ACCESSION NUMBER: 2004:802766 ZCAPLUS Full-text

DOCUMENT NUMBER: 141:314337

TITLE: Preparation of vicinally-disubstituted azaheterocyclyl aromatic compounds as inhibitors of Tie-2 kinase

INVENTOR(S): Parks, Jason Jevious; Bannen, Lynne Canne; Brown, S. David; Cheng, Wei; Cheung, Atwood Kim; Dalrymple, Lisa Esther; Epshteyn, Sergey; Ibrahim, Mohamed Abdulkader; Jammalamadaka, Vasu; Leahy, James William; Lewis, Gary Lee; Mac, Morrison B.; Mann, Larry W.; Nuss, John M.; Noguchi, Robin Tammie; Ridgway, Brian Hugh; Sangalang, Joan C.; Schnepf, Kevin Luke; Shi, Xian; Williams, Matthew A.; Xu, Wei; Khoury, Richard

PATENT ASSIGNEE(S): Exelixis Inc., USA

SOURCE: PCT Int. Appl., 215 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083235	A2	20040930	WO 2004-US8579	20040319
WO 2004083235	A3	20050303		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004221812	A1	20040930	AU 2004-221812	20040319
CA 2517291	A1	20040930	CA 2004-2517291	20040319
EP 1608373	A2	20051228	EP 2004-757665	20040319
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
JP 2006524682	T	20061102	JP 2006-507414	20040319

10/576653

US 20070275952	A1	20071129	US 2007-549300	20070131
PRIORITY APPLN. INFO.:			US 2003-456565P	P 20030319
			WO 2004-US8579	W 20040319
OTHER SOURCE(S):	MARPAT 141:314337			
GI				



AB Compds. I [Ar = a five- or six-membered heteroarom. ring containing 1-3 heteroatoms in which the two substituents are ortho to each other (vicinal); A = bond, CH₂; L = (CH₂)_m, (CH₂)_mNR₃, (CH₂)_mO, (CH₂)_mS, (CH₂)_mS(:O), (CH₂)_mSO₂; M = R₃R₄N, R₃O; R₁ = H, R₃R₄N, R₃R₄NCH₂, MC(:O), MCH₂C(:O); R₂ = H, halogen, oxo, NC, H₂N, O₂N, (un)substituted alkoxy, amino, alkylthio, etc.; multiple R₂ may form a three- to seven-membered ring; R₃ = H, (un)substituted alkyl, aryl, aralkyl, heterocyclyl, heterocycloalkyl; R₄ = R₃, R₃SO₂, R₃NSO₂, R₃O₂C, R₃NC(:O), R₃C(:O); R₃R₄N may also form a five- to seven-membered heterocyclic ring which may contain a second heteroatom selected from N, O, P, or S; Y = bond, CH₂, O, S, S(:O), SO₂, NR₃; W = R₂CC, R₄N, S, S(:O), SO₂, O; Z = R₃ or an (un)substituted five- to seven-membered heterocycle; m, q = 1-3] such as II are prepared as inhibitors of protein kinases such as the human protein kinase Tie-2 for the inhibition of undesired cellular activity such as proliferation. II is prepared in four steps; nucleophilic substitution of 3,4-dichloro-1,2,5-thiadiazole with Boc-piperazine in DMF, nucleophilic substitution of the remaining chloro moiety with 4-pyridinemethanol and potassium tert-butoxide in tert-butanol, removal of the Boc group with HCl in dioxane, and reaction of the amine dihydrochloride salt with 3,5-bis(trifluoromethyl)phenyl isocyanate and triethylamine in dichloromethane yields II. II inhibits human Tie-2 kinase with an IC₅₀ value of < 50 nM. Data on the inhibition of Tie-2 kinase by compds. of the invention is provided.

L35 ANSWER 12 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 12

ACCESSION NUMBER: 2004:493723 ZCAPLUS [Full-text](#)

DOCUMENT NUMBER: 141:54195


TITLE: Preparation of oxindole derivatives as kinase modulators

INVENTOR(S): Bannen, Lynne Canne; Brown, S. David; Cheng, Wei; Co, Erick Wang; Nuss, John M.; Kim, Moon Rwan; Klein, Rhett Ronald; Le, Donna T.; Lew, Amy; Mac, Morrison B.; Parks, Jason Jevius; Wen, Zhaoyang; Xu,


We1
 PATENT ASSIGNEE(S): Exelixis, Inc., USA
 SOURCE: PCT Int. Appl., 120 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050681	A2	20040617	WO 2003-US36567	20031114
WO 2004050681	A3	20041104		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2506546	A1	20040617	CA 2003-2506546	20031114
AU 2003302665	A1	20040623	AU 2003-302665	20031114
EP 1581309	A2	20051005	EP 2003-812437	20031114
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006510727	T	20060330	JP 2004-570758	20031114
US 20060122171	A1	20060608	US 2005-533555	20050502
PRIORITY APPLN. INFO.:			US 2002-426680P	P 20021115
			US 2003-470674P	P 20030514
			WO 2003-US36567	W 20031114

OTHER SOURCE(S): MARPAT 141:54195
 GI



I



II

AB The title compds. I [W = N or CR1; R1 = H, halo, trihaloalkyl, CN, NH2, NO2, OR6, N=CNR6R7, N(R6)C(NR8)NR6R7, SR6, S(O)1-2R6, SO2NR6R7, CO2R6, etc.; L = O, S(O)0-2, or NR3; Q = C or N, when Q = N, then R4 does not exist; R2, R3 = H or R7; R4, R5 = H, OR6, NR6R7, S(O)0-2R6, SO2NR6R7, CO2R6, C(O)NR6R7, N(R6)SO2R6, NC(O)2R6, C(O)R7, CN, NO2, NH2, halo, trihaloalkyl, R7; or R4, R5 when taken together, form a five or six-membered aromatic ring containing 0-2 N; R6, R7 = H, (substituted)(aryl)alkyl, (substituted)heterocyclylalkyl, (substituted)aryl, (substituted)heterocyclyl, with proviso or R6, R7 = when taken together with a common N to which they are attached, form a five to seven-membered heterocyclic ring containing at least one addnl. heteroatom selected from N, O, S, or P; R8 = H, NO2, CN, OR6, or (substituted)alkyl; X = (substituted)(hetero)aromatic ring; K = O, S, (substituted)amino] were prepared as kinase modulators to treat kinase-dependent diseases and conditions. For example compound II was prepared in a multi-step synthesis starting from 4-methylimidazole. The latter inhibited KDR and EGFR with IC50 < 50 nM.

L35 ANSWER 13 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 13

ACCESSION NUMBER: 2003:1006921 ZCAPLUS Full-text

DOCUMENT NUMBER: 140:42210

TITLE: Preparation of 1-sulfonyl-2-piperazinehydroxamic acids as selective inhibitors of human ADAM-10 for treating cancer, arthritis and diseases related to angiogenesis
INVENTOR(S): Bannen, Lynne Canne; Co, Erick W.; Jammalamadaka, Vasu; Nuss, John M.; Kim, Moon Hwan; Le Tra, Donna; Lew, Amy; Mac, Morrison B.; Mamo, Shumeye; Wen, Zhaoyang; Xu, Wei

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003106381	A2	20031224	WO 2003-US18262	20030611
WO 2003106381	A3	20040415		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2485346	A1	20031224	CA 2003-2485346	20030611
AU 2003237532	A1	20031231	AU 2003-237532	20030611
EP 1511488	A2	20050309	EP 2003-736979	20030611
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005533789	T	20051110	JP 2004-513217	20030611
US 20060199820	A1	20060907	US 2005-518110	20051026
PRIORITY APPLN. INFO.:			US 2002-388326P	P 20020612

OTHER SOURCE(S):

MARPAT 140:42210

GI




AB The present invention provides 1-sulfonyl-2-piperazinehydroxamic acids (shown as I; variables defined below; e.g. II) useful for inhibiting the ADAM-10 protein, with selectivity vs. MMP-1. Inhibition activities of 66 examples of I towards ≤ 8 metalloproteinases are tabulated. Such compds. are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biol. processes. The present invention also comprises pharmaceutical compns. comprising ≥ 1 ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compns. are useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. Correspondingly, the invention also comprises methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role. A method of preparation of sulfonyl halide intermediates is claimed. For example, [4-(4-fluorophenoxy)-3,5-difluorophenyl]sulfonyl chloride was prepared in 3 steps (105, 98 and 83 % yields) starting from 3,4,5-trifluoronitrobenzene, 4-fluorophenol, and Cs_2CO_3 in DMF and involving intermediates 4-(4-fluorophenoxy)-3,5-difluoronitrobenzene and 4-(4-fluorophenoxy)-3,5- difluoroaniline. The prepared [4-(4-fluorophenoxy)-3,5- difluorophenyl]sulfonyl chloride was used in a 5-step procedure (65, 78, -, 69 and 62 % yields) to give II involving intermediates (R)-1-[[4-(4-fluorophenoxy)-3,5-difluorophenyl]sulfonyl]-4-boc-piperazine-2-carboxylic acid, Me (R)-1-[[4-(4-fluorophenoxy)-3,5- difluorophenyl]sulfonyl]-4-boc-piperazine-2-carboxylate, Me (R)-1-[[4-(4-fluorophenoxy)-3,5- difluorophenyl]sulfonyl]piperazine-2- carboxylate trifluoroacetate and Me (R)-1-[[4-(4-fluorophenoxy)-3,5- difluorophenyl]sulfonyl]-4-(ethoxycarbonyl)piperazine-2-carboxylate. Although the methods of preparation of I are not claimed, several example prepn. and characterization data for 66 examples of I are included. For I: L1 is -C(O)-, -S(O)₂-, or -(CH₂)_n-; R1 is -H, -OR11, -(CH₂)_nR11, -C(O)R11, or -NR12R13; R2 is -R21-L2-R22 (R21 is saturated or mono- or poly- unsatd. C5-C14-mono- or fused poly- cyclic hydrocarbyl, optionally containing one or two annular heteroatoms per ring and (un)substituted with 1-3 R50 substituents; L2 is -O-, -C(O)-, -CH₂-, -NH-, -S(O₂- or a direct bond; R22 is saturated or mono- or poly- unsatd. C5-C14-mono- or fused polycyclic hydrocarbyl, optionally containing one or two annular heteroatoms per ring and (un)substituted with 1-3 R50 substituents); n = 0-3; provided that an O or S is not singly bonded to another O or S in a chain of atoms; addnl. details are given in the claims.

L35 ANSWER 14 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 14
 ACCESSION NUMBER: 2003:892800 ZCAPLUS Full-text
 DOCUMENT NUMBER: 139:395950
 TITLE: Preparation of substituted pyrazines as protein kinase modulators
 INVENTOR(S): Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tesfai, Zerom; Wang, Longcheng; Co, Erick Wang; Epshteyn, Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko, Larisa; Anand, Neel Kumar; Tsang, Tsze H.; Nuss, John M.; Peto, Csaba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepp, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa Esther; Forsyth, Timothy Patrick; Huynh, Tai Phat; Mann, Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy
 PATENT ASSIGNEE(S): Exelixis, Inc., USA
 SOURCE: PCT Int. Appl., 468 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093297	A2	20031113	WO 2003-US13869	20030502
WO 2003093297	A3	20040701		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2484209	A1	20031113	CA 2003-2484209	20030502
AU 2003234464	A1	20031117	AU 2003-234464	20030502
EP 1501514	A2	20050202	EP 2003-728690	20030502
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005530760	T	20051013	JP 2004-501436	20030502
US 20060211709	A1	20060921	US 2005-513081	20050727
PRIORITY APPLN. INFO.:			US 2002-377933P	P 20020503
			WO 2003-US13869	W 20030502

OTHER SOURCE(S): MARPAT 139:395950
 GI



AB This invention relates to compds. I [R1 = H, halo, CN, etc.; R2, R3 = H, alkyl, aryl, etc.; R4 = H, alkyl, aryl, etc.; Z = N, CH; A = CO, CS, C((NR6)), R7 (when A = R7, E does not exist); R6 = H, NO2, CN, etc.; R7 = (un)substituted 5-7 membered heterocyclyl; E = NR8R9, NNR2R3, OR4, etc.; R8 = H, alkyl; R9 = H, heteroarylalkyl, etc.; NR8R9 = (un)substituted 5-7 membered heteroalicycyl; W = 6-10 membered arylene, 5-10 membered heteroarylene; X = a bond, (un)substituted alkylene, O(CH2)2-30, etc.; Y = H, alkyl, aryl, etc.; with provisos] for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compns. containing such compds. Even more specifically, the invention relates to compds. I that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Preparation of representative compds. I is described. Thus, amidation of 3-amino-6-phenylpyrazinecarboxylic acid (preparation given) with benzylamine afforded 6% 3-amino-6-phenyl-N- (phenylmethyl)pyrazine-2-carboxamide which showed IC50 of 10,000 nM or greater against Chk1. Table presenting activity data with respect to Chk1 for over 1000 compds. I is given. Methods of therapeutically or prophylactically using the compds. I and compns. to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amts. of such compds.

L35 ANSWER 15 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 15

ACCESSION NUMBER: 2003:491172 ZCAPLUS Full-text

DOCUMENT NUMBER: 139:69520

TITLE: Preparation of N-sulfonyl amino acid hydroxamide derivatives as human ADAM-10 inhibitors
INVENTOR(S): Brown, S. David; Canne, Lynne; Co, Erick W.; Jammalamadaka, Vasu; Khoury, Richard G.; Kim, Moon Hwan; Le, Donna T.; Lew, Amy; Mac, Morrison B.; Mamo, Shumeye; Nuss, John M.; Prisbylla, Michael P.; Xu, Wei

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 144 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051825	A1	20030626	WO 2002-US39816	20021213
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2473938	A1	20030626	CA 2002-2473938	20021213
AU 2002346724	A1	20030630	AU 2002-346724	20021213
EP 1461313	A1	20040929	EP 2002-784794	20021213
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
JP 2005513065	T	20050512	JP 2003-552713
US 20050227973	A1	20051013	US 2005-498338
PRIORITY APPLN. INFO.:			US 2001-340179P
			WO 2002-US39816
			P 20011214
			W 20021213

OTHER SOURCE(S): MARPAT 139:69520

AB The invention provides amino acid derivs. R5SO2NR4CHR3CONR2OR1 [R1 is H, alkyl, alkanoyl, (un)substituted arylalkyl or arylalkanoyl; R2 is any group given for R1 plus alkoxy; R3 is -Z-Q-J, where Z is (un)substituted alk(en)yl, alkoxyalkyl, or alkylthioalkyl; Q is a bond, CO, (un)substituted aryl, heteroaryl, or heterocycloalkyl; J is an amino group, including ureido groups; R4 is H, (un)substituted alkyl or arylalkyl; R5 is -M-G-A, where M and A are (un)substituted aryl or heteroaryl; G is a bond, CH2, -alkyl-O-, -O-alkyl-, O, S, SO, or SO2 (with provisos)] useful for inhibiting the ADAM-10 protein, also known as human Kuzbanian. Such compds. are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biol. processes. Pharmaceutical compns. comprising one or more ADAM-10 inhibitors are useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. The invention also provides methods for making bis-aryl ether sulfonyl chloride intermediates. Thus, claimed compound N2-[6-(3-fluorophenyl)pyridin-3-yl]sulfonyl-N1-hydroxy-D-argininamide showed IC50 < 50 nM for inhibition of ADAM-10.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 16 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:101707 ZCAPLUS Full-text

DOCUMENT NUMBER: 141:29645

TITLE: Parity-violating electroweak asymmetry in .vector.ep scattering

AUTHOR(S): Aniol, K. A.; Armstrong, D. S.; Averett, T.; Baylac, M.; Burtin, E.; Calarco, J.; Cates, G. D.; Cavata, C.; Chai, Z.; Chang, C. C.; Chen, J.-P.; Chudakov, E.; Cisbani, E.; Coman, M.; Dale, D.; Deur, A.; Djawotho, P.; Epstein, M. B.; Escoffier, S.; Ewell, L.; Falletto, N.; Finn, J. M.; Fissum, K.; Fleck, A.; Frois, B.; Frullani, S.; Gao, J.; Garibaldi, F.; Gasparian, A.; Gerstner, G. M.; Gilman, R.; Glamazdin, A.; Gomez, J.; Gorbenko, V.; Hansen, O.; Hersman, F.; Higinbotham, D. W.; Holmes, R.; Holtrop, M.; Humensky, T. B.; Incerti, S.; Iodice, M.; de Jager, C. W.; Jardillier, J.; Jiang, X.; Jones, M. K.; Jorda, J.; Jutier, C.; Kahl, W.; Kelly, J. J.; Kim, D. H.; Kim, M.-J.; Kim, M. S.; Kominis, I.; Kooijman, E.; Kramer, K.; Kumar, K. S.; Kuss, M.; LeRose, J.; De Leo, R.; Leuschner, M.; Lhuillier, D.; Liang, M.; Liyanage, N.; Lourie, R.; Madey, R.; Malov, S.; Margaziotis, D. J.; Marie, F.; Markowitz, P.; Martino, J.; Mastromarino, P.; McCormick, K.; McIntyre, J.; Mezziani, Z.-E.; Michaels, R.; Milbrath, B.; Miller, G. W.; Mitchell, J.; Morand, L.; Neyret, D.; Pedrisat, C.; Petratos, G. G.; Pomatsalyuk, R.; Price, J. S.; Prout, D.; Punjabi, V.; Pussieux, T.; Quemener, G.; Ransome, R. D.; Relyea, D.; Roblin, Y.; Roche, J.; Rutledge, G. A.; Rutt, P. M.; Rvachev, M.; Sabatie, F.; Saha, A.; Souder, P. A.; Spradlin, M.; Strauch, S.; Suleiman, R.; Templeon, J.; Teresawa, T.; Thompson, J.; Tieulent, R.; Todor, L.; Tonguc, B. T.; Ulmer, P. E.; Urciuoli, G. M.; Vlahovic, B.; Wijesooriya, K.; Wilson, R.; Wojtkhowski, B.; Woo, R.; Xu, W.; Younus, I.;

Zhang, C.
 CORPORATE SOURCE: The HAPPEX Collaboration, California State University,
 Los Angeles, CA, 90032, USA
 SOURCE: Los Alamos National Laboratory, Preprint Archive,
 Nuclear Experiment (2004) 1-85, arXiv:nucl-ex/0402004,
 5 Feb 2004
 CODEN: LNNEFO
 URL: <http://xxx.lanl.gov/pdf/nucl-ex/0402004>
 PUBLISHER: Los Alamos National Laboratory
 DOCUMENT TYPE: Preprint
 LANGUAGE: English
 AB We measured the parity-violating electroweak asymmetry in the elastic
 scattering of polarized electrons from protons. Significant contributions to
 this asymmetry could arise from the contributions of strange form factors in
 the nucleon. The measured asymmetry is $A = -15.05 \pm 0.98(\text{stat}) \pm 0.56(\text{syst})$
 ppm at the kinematic point $\langle 0 \rangle_{\text{lab}} = 12.3^\circ$ and $\langle Q^2 \rangle =$
 0.477 (GeV/c)^2 . Based on these data as well as data on electromagnetic form
 factors, we extracted the linear combination of strange form factors $G_E +$
 $0.392 G_M = 0.014 \pm 0.020 \pm 0.010$, where the first error arises from this
 experiment and the second arises from the electromagnetic form factor data.
 This paper provides a full description of the special exptl. techniques
 employed for precisely measuring the small asymmetry, including the first use
 of a strained GaAs crystal and a laser-Compton polarimeter in a fixed target
 parity-violation experiment
 REFERENCE COUNT: 146 THERE ARE 146 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L35 ANSWER 17 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:536906 ZCAPLUS Full-text
 DOCUMENT NUMBER: 141:231735
 TITLE: Parity-violating electroweak asymmetry in .vector.ep
 scattering
 AUTHOR(S): Aniol, K. A.; Armstrong, D. S.; Averett, T.; Baylac,
 M.; Burtin, E.; Calarco, J.; Cates, G. D.; Cavata, C.;
 Chai, Z.; Chang, C. C.; Chen, J.-P.; Chudakov, E.;
 Cisbani, E.; Coman, M.; Dale, D.; Deur, A.; Djawotho,
 P.; Epstein, M. B.; Escoffier, S.; Ewell, L.;
 Falletto, N.; Finn, J. M.; Fissum, K.; Fleck, A.;
 Frois, B.; Frullani, S.; Gao, J.; Garibaldi, F.;
 Gasparian, A.; Gerstner, G. M.; Gilman, R.; Glamazdin,
 A.; Gomez, J.; Gorbenco, V.; Hansen, O.; Hersman, F.;
 Higinbotham, D. W.; Holmes, R.; Holtrop, M.; Humensky,
 T. B.; Incerti, S.; Iodice, M.; de Jager, C. W.;
 Jardiillier, J.; Jiang, X.; Jones, M. K.; Jorda, J.;
 Jutier, C.; Kahl, W.; Kelly, J. J.; Kim, D. H.; Kim,
 M.-J.; Kim, M. S.; Kominis, I.; Kooijman, E.;
 Kramer, K.; Kumar, K. S.; Kuss, M.; LeRose, J.; De
 Leo, R.; Leuschner, M.; Lhuillier, D.; Liang, M.;
 Liyanage, N.; Lourie, R.; Madey, R.; Malov, S.;
 Margaziotis, D. J.; Marie, F.; Markowitz, P.; Martino,
 J.; Mastromarino, P.; McCormick, K.; McIntyre, J.;
 Meziani, Z.-E.; Michaels, R.; Milbrath, B.; Miller, G.
 W.; Mitchell, J.; Morand, L.; Neyret, D.; Pedrisat,
 C.; Petratos, G. G.; Pomatsalyuk, R.; Price, J. S.;
 Prout, D.; Punjabi, V.; Pussieux, T.; Quemener, G.;
 Ransome, R. D.; Relyea, D.; Roblin, Y.; Roche, J.;
 Rutledge, G. A.; Rutt, P. M.; Rvachev, M.; Sabatie,
 F.; Saha, A.; Souder, P. A.; Spradlin, M.; Strauch,
 S.; Suleiman, R.; Templon, J.; Teresawa, T.; Thompson,

J.; Tieulent, R.; Todor, L.; Tonguc, B. T.; Ulmer, P. E.; Urciuoli, G. M.; Vlahovic, B.; Wijesooriya, K.; Wilson, R.; Wojtsekhowski, B.; Woo, R.; Xu, W.; Younus, I.; Zhang, C.

CORPORATE SOURCE: California State University, Los Angeles, Los Angeles, CA, 90032, USA

SOURCE: Physical Review C: Nuclear Physics (2004), 69(6), 065501/1-065501/35

CODEN: PRVCAN; ISSN: 0556-2813

PUBLISHER: American Physical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We have measured the parity-violating electroweak asymmetry in the elastic scattering of polarized electrons from protons. Significant contributions to this asymmetry could arise from the contributions of strange form factors in the nucleon. The measured asymmetry is $A = -15.05 \pm 0.98(\text{stat}) \pm 0.56(\text{syst})$ ppm at the kinematic point $\langle Q^2 \rangle = 12.3^\circ$ and $\langle Q^2 \rangle = 0.477$ (GeV/c)². Based on these data as well as data on electromagnetic form factors, we extract the linear combination of strange form factors $G_E + 0.392 G_M = 0.014 \pm 0.020 \pm 0.010$, where the first error arises from this experiment and the second arises from the electromagnetic form factor data. This paper provides a full description of the special exptl. techniques employed for precisely measuring the small asymmetry, including the first use of a strained GaAs crystal and a laser-Compton polarimeter in a fixed target parity-violation experiment

REFERENCE COUNT: 148 THERE ARE 148 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 18 OF 31 ZCAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2003:833747 ZCAPLUS Full-text

DOCUMENT NUMBER: 140:170624

TITLE: Measurement of the mass difference $m(D_s^+) - m(D^+)$ at CDF II

AUTHOR(S): Acosta, D.; Affolder, T.; Ahn, M. H.; Akimoto, T.; Albrow, M. G.; Alcorn, B.; Alexander, C.; Allen, D.; Allspach, D.; Amaral, P.; Ambrose, D.; Amendolia, S. R.; Amidei, D.; Amundson, J.; Anastassov, A.; Anderson, J.; Anikeev, K.; Annovi, A.; Antos, J.; Aoki, M.; Apollinari, G.; Arguin, J.-F.; Arisawa, T.; Artikov, A.; Asakawa, T.; Ashmanskas, W.; Attal, A.; Avanzini, C.; Azfar, F.; Azzi-Bacchetta, P.; Babik, M.; Bacchetta, N.; Bachacou, H.; Badgett, W.; Bailey, S.; Bakken, J.; Barbaro-Galtieri, A.; Bardi, A.; Bari, M.; Barker, G.; Barnes, V. E.; Barnett, B. A.; Baroiant, S.; Barone, M.; Barsotti, E.; Basti, A.; Bauer, G.; Beckner, D.; Bedeschi, F.; Behari, S.; Belforte, S.; Bell, W. H.; Bellendir, G.; Bellettini, G.; Bellinger, J.; Benjamin, D.; Beretvas, A.; Berg, B.; Bhatti, A.; Binkley, M.; Bisello, D.; Bishai, M.; Blair, R. E.; Blocker, C.; Bloom, K.; Blumenfeld, B.; Bocci, A.; Bodek, A.; Bogdan, M.; Bolla, G.; Bolshov, A.; Booth, P. S. L.; Bortoletto, D.; Boudreau, J.; Bourov, S.; Bowden, M.; Box, D.; Bromberg, C.; Brown, Brozovic, M.; Brubaker, E.; Buckley-Geer, L.; Budagov, J.; Budd, H. S.; Burkett, K.; Busetto, G.; Bussey, P.; Byon-Wagner, A.; Byrum, K. L.; Cabrera, S.; Calafiura, P.; Campanelli, M.; Campbell, M.; Canal, F.; Canepa, A.; Carithers, W.; Carlsmith, D.; Carosi, R.; Carrell, K.; Carter, H.; Caskey, W.; Castro, A.;

Cauz, D.; Cerri, A.; Cerri, C.; Cerrito, L.;
 Chandler, J. T.; Chapman, J.; Chappa, S.; Chen, C.;
 Chen, Y. C.; Cheng, M. T.; Chertok, M.; Chiarelli, G.;
 Chirikov-Zorin, I.; Chlachidze, G.; Chlebana, F.; Cho,
 I.; Cho, K.; Chokheli, D.; Chu, M. L.; Chung, J. Y.;
 Chung, W.-H.; Chung, Y. S.; Ciobanu, C. I.; Ciocci, M.
 A.; Cisko, S.; Clark, A. G.; Coca, M.; Coile, K.;
 Colijn, A. P.; Colombo, R.; Connolly, A.; Convery, M.;
 Conway, J.; Cooper, G.; Cordelli, M.; Cortiana, G.;
 Cranshaw, J.; Cudzewicz, R.; Culbertson, R.; Currat,
 C.; Cyr, D.; Dagenhart, D.; DalMonte, L.; DaRocco, S.;
 D'Auria, S.; Davila, R.; Dawson, J.; Dawson, T.; de
 Barbaro, P.; DeBaun, C.; De Cecco, S.; Dell'Agnello,
 S.; Dell'Orso, M.; DeMaat, R.; Demar, P.; Demers, S.;
 Demortier, L.; Deninno, M.; De Pedis, D.; Derwent, P.
 F.; Derylo, G.; Devlin, T.; Dionisi, C.; Dittmann, J.
 R.; Doksus, P.; Dominguez, A.; Donati, S.; Donno, F.;
 D'Onofrio, M.; Dorigo, T.; Downing, R.; Drake, G.;
 Drennan, C.; Drollinger, V.; Dunietz, I.; Dyer, A.;
 Ebina, K.; Eddy, N.; Ely, R.; Engels, E.; Erbacher,
 R.; Erdmann, M.; Errede, D.; Errede, S.; Eusebi, R.;
 Fang, H.-C.; Farrington, S.; Feild, R. G.; Feindt, M.;
 Fernandez, J. P.; Ferretti, C.; Field, R. D.; Fiori,
 I.; Fischler, M.; Flanagan, G.; Flaugh, B.;
 Flores-Castillo, L. R.; Foland, A.; Forrester, S.;
 Foster, G. W.; Franklin, M.; Frisch, H.; Fromm, J.;
 Fujii, Y.; Furic, I.; Galeotti, S.; Galet, G.; Gallas,
 A.; Gallinaro, M.; Ganel, O.; Garcia, C.;
 Garcia-Sciveres, M.; Garfinkel, A. F.; Garwacki, M.;
 Garzoglio, G.; Gay, C.; Gerberich, H.; Gerdes, D. W.;
 Gerchtein, E.; Gerstenschlager, J.; Giacchetti, L.;
 Giagu, S.; Giannethi, P.; Gibson, A.; Gillespie, G.,
 Jr.; Gingu, C.; Ginsburg, C.; Giolo, K.; Giordani, M.;
 Glagolev, V.; Glenzinski, D.; Glossen, R.; Gold, M.;
 Goldschmidt, N.; Goldstein, D.; Goldstein, J.; Gomez,
 G.; Goncharov, M.; Gonzalez, H.; Gordon, S.; Gorelov,
 I.; Goshaw, A. T.; Gotra, Y.; Goulianos, K.; Grado,
 J.; Gregori, M.; Gresele, A.; Griffin, T.; Grim, G.;
 Grimm, C.; Gromoll, S.; Grosso-Pilcher, C.; Gu,
 Guarino, V.; Guenther, M.; Guimaraes da Costa, J.;
 Haber, C.; Hahn, A.; Hahn, K.; Hahn, S. R.;
 Halkiadakis, E.; Hall, C.; Handler, R.; Haney, M.;
 Hao, W.; Hapacher, F.; Hara, K.; Hare, M.; Harr, R.
 F.; Harrington, J.; Harris, R. M.; Hartmann, F.;
 Hatakeyama, K.; Hauser, J.; Hawke, T.; Jays, C.;
 Heider, E.; Heinemann, B.; Heinrich, J.; Heiss, A.;
 Hennecke, M.; Herber, R.; Herndon, M.; Herren, M.;
 Hicks, D.; Hill, C.; Hirschebuehl, D.; Hocker, A.;
 Hoff, J.; Hoffman, K. D.; Hoftiezer, J.; Holloway, A.;
 Holloway, L.; Holm, S.; Holmgren, D.; Hou, S.;
 Houlden, M. A.; Howell, J.; Hrycyk, M.; Hrycyk, M.;
 Hubbard, P.; Hughes, R. E.; Huffman, B. T.; Humbert,
 J.; Huston, J.; Ikado, K.; Incandela, J.; Introzzi,
 G.; Iori, M.; Ishizawa, I.; Issever, C.; Ivanov, A.;
 Iwata, Y.; Iyutin, B.; James, E.; Jang, D.; Jarrell,
 J.; Jeans, D.; Jensen, H.; Jetton, R.; Johnson, M.;
 Jones, M.; Jones, T.; Jun, S. Y.; Junk, T.;
 Kallenbach, J.; Kamon, T.; Kang, J.; Karagoz Unel, M.;
 Karchin, P. E.; Kartal, S.; Kasha, H.; Kasten, M.;
 Kato, Y.; Kemp, Y.; Kennedy, R. D.; Kephart, K.;

Kephart, R.; Khazins, D.; Khotilovich, V.;
 Killinister, B.; Kim, B. J.; Kim, D. H.; Kim, H. S.;
 Kim, J.; Kim, M. J.; Kim, M. S.; Kim, S. B.; Kim, S.
 H.; Kim, T. H.; Kim, Y. K.; King, B. T.; Kirby, M.;
 Kirk, M.; Kirsch, L.; Klein, R.; Klimenko, S.; Knapp,
 M.; Knoblauch, D.; Knuteson, B.; Kobayashi, H.;
 Koelin, P.; Kondo, K.; Kong, D. J.; Konigsberg, J.;
 Kononenko, W.; Kordas, K.; Korn, A.; Korytov, A.;
 Kotelnikov, K.; Kotwal, A.; Kovalev, A.; Kowalkowski,
 J.; Kraus, J.; Kravchenko, I.; Kreymer, A.; Kroll, J.;
 Kruse, M.; Krutelyov, V.; Kuhlmann, S. E.; Kumar, A.;
 Kuznetsova, N.; Laasanen, A. T.; Lai, S.; Lami, S.;
 Lammel, S.; Lamore, D.; Lancaster, J.; Lancaster, M.;
 Lander, R.; Lanfranco, G.; Lannon, K.; Lath, A.;
 Latino, G.; Lauhakangas, R.; Lazzizzera, I.; Le, Y.;
 LeCompte, T.; Lee, J.; Lee, J.; Lee, K.; Lee, S. W.;
 Lei, C. M.; Leininger, M.; Leonardi, G. L.; Leonardo,
 N.; Leone, S.; Levshina, T.; Lewis, F.; Lewis, J. D.;
 Li, K.; Lin, C. S.; Lindgren, M.; Liss, T. M.;
 Litvintsev, D. O.; Liu, T.; Lin, Y.; Lobban, O.;
 Lockyer, N. S.; Loginov, A.; Loken, J.; Loreti, M.;
 Loskot, J.; Loverre, P. F.; Luccchesi, D.; Lukens, P.;
 Lutz, P.; Lyons, L.; Lys, J.; MacNerland, J.;
 MacQueen, D.; Madorsky, A.; Madrak, R.; Maeshima, K.;
 Maksimovic, P.; Malferrari, L.; Mammini, P.; Manca,
 G.; Mandrichenko, I.; Manea, C.; Marginean, R.;
 Marraffino, J.; Martin, A.; Martin, M.; Martin, V.;
 Martinez, M.; Maruyama, T.; Matsunaga, H.; Mayer, J.;
 Mayers, G. M.; Mazzanti, P.; McFarland, K. S.;
 McGivern, D.; McIntyre, P. M.; McNamara, P.; McNulty,
 R.; Menzemer, S.; Menzione, A.; Merkel, P.; Mesrobian,
 C.; Messina, A.; Meyer, A.; Miao, T.; Michael, N.;
 Miller, J. S.; Miller, L.; Miller, R.; Miquel, R.;
 Miscetti, S.; Mitselmakher, G.; Miyamoto, A.;
 Miyazaki, Y.; Mizicko, D.; Moccia, S.; Moggi, A.;
 Moggi, N.; Montero, S.; Moore, R.; Moore, T.; Morris,
 L.; Morsani, F.; Moulik, T.; Mukherjee, A.; Mulhearn,
 M.; Muller, T.; Mumford, R.; Munar, A.; Murat, P.;
 Murgia, S.; Nachtman, J.; Nagaslaev, V.; Nahn, S.;
 Nakamura, I.; Nakano, I.; Napier, A.; Napor, R.;
 Necula, V.; Nelson, C.; Nelson, T.; Neu, C.; Neubauer,
 M. S.; Neuberger, D.; Newby, W.; Newcomer, F. M.;
 Newman-Holmes, C.; Niell, F.; Nielsen, J.; Nicollerat,
 A.-S.; Nigmanov, T.; Niu, H.; Nodulman, L.; Noe, W.,
 Jr.; Oesterberg, K.; Ogawa, T.; Oh, S.; Oh, Y. D.;
 Ohl, K.; Ohsugi, T.; Oishi, R.; Okusawa, T.; Oldeman,
 R.; Orava, R.; Oregudos, W.; Orr, S.; Pagani, G.;
 Pagliarone, C.; Palmonari, F.; Ramos, I.; Panacek, S.;
 Pantano, D.; Paoletti, R.; Papadimitriou, V.; Pasetes,
 R.; Pashapour, S.; Passuello, D.; Paterno, M.;
 Patrick, J.; Pauletta, G.; Paulini, M.; Pauly, T.;
 Paus, C.; Pavlicek, V.; Pavlon, S.; Pellett, D.;
 Penzo, A.; Perington, B.; Petragnani, G.; Petravick,
 D.; Phillips, T. J.; Photos, F.; Piacentino, G.;
 Picciolo, C.; Piccoli, L.; Piedra, J.; Pitts, K. T.;
 Plunkett, R.; Pompos, A.; Pondrom, L.; Pope, G.;
 Poukhov, O.; Prakashyn, F.; Pratt, T.; Profeti, A.;
 Pronko, A.; Proudfoot, J.; Punzi, G.; Rademacker, J.;
 Raffaelli, F.; Rakitine, A.; Rappoccio, S.; Ratnikov,
 F.; Rauch, J.; Ray, H.; Rechenmacher, R.; Reia, S.;

Reichold, A.; Rekovic, V.; Renton, P.; Rescigno, M.; Rimondi, F.; Rinnert, K.; Ristori, L.; Riveline, M.; Rivetta, C.; Robertson, W. J.; Robson, A.; Rodrigo, T.; Rolli, S.; Roman, M.; Rosenberg, S.; Rosenson, L.; Roser, R.; Rossin, R.; Rott, C.; Ruiz, A.; Russ, J.; Ryan, D.; Saarikko, H.; Sabik, S.; Sadler, L.; Safonov, A.; St. Denis, R.; Sakumoto, W. K.; Saltzberg, D.; Sanchez, C.; Sanders, H.; Sanders, R.; Sandrew, M.; Sansoni, A.; Santi, L.; Sarkar, S.; Sarraj, H.; Sarraj, J.; Sato, H.; Savard, P.; Schemnitz, P.; Schlabach, P.; Schmidt, E. E.; Schmidt, J.; Schmidt, M. P.; Schmitt, M.; Schmitt, R.; Schmitz, M.; Schofield, G.; Schuh, K.; Schultz, K.; Scodellaro, L.; Scott, L.; Scribano, A.; Scuri, F.; Sedov, A.; Segler, S.; Seidel, S.; Seiya, Y.; Semenov, A.; Semeria, F.; Sexton-Kennedy, L.; Sfiligoi, I.; Shallenberger, J.; Shapiro, M. D.; Shaw, T.; Shears, T.; Shenai, A.; Shepard, P. F.; Shimojima, M.; Shochet, M.; Shon, Y.; Shoun, M.; Sidoti, A.; Siegrist, J.; Sieh, C.; Siket, M.; Sill, A.; Silva, R.; Simaitis, V.; Sinervo, P.; Sirotenko, I.; Sisakyan, A.; Skiba, A.; Slaughter, A. J.; Sliwa, K.; Smith, J.; Snider, F. D.; Snihur, R.; Somalwar, S. V.; Spalding, J.; Spezziga, M.; Spiegel, L.; Spinella, F.; Stuart, D.; Stuermer, W.; Sukhanov, A.; Sumorok, K.; Sun, H.; Suzuki, T.; Syu, J.; Szymulanski, A.; Taffard, A.; Takach, S. F.; Takano, H.; Takashima, R.; Takeuchi, Y.; Takikawa, K.; Tamburello, P.; Tanaka, M.; Tanaka, R.; Tang, D.; Tanimoto, N.; Tannenbaum, B.; Tapprogge, S.; Taylor, R. D.; Teafae, G.; Tecchio, M.; Teng, P. K.; Terashi, K.; Terentjeva, T.; Tesarek, R. J.; Tether, S.; Thom, J.; Thomas, A.; Thompson, A. S.; Thomson, E.; Thurman-Keup, R.; Timm, S.; Tipton, P.; Tkaczyk, S.; Toback, D.; Tollefson, K.; Tonelli, D.; Tonnesmann, M.; Torretta, D.; Trimby, C.; Trischuk, W.; Trumbo, J.; Tseng, J.; Tsuchiya, R.; Tsuno, S.; Tsybychev, D.; Turini, N.; Turner, M.; Ukegawa, F.; Unverhau, T.; Uozumi, S.; Usynin, D.; Vacavant, L.; Vaiculis, T.; Van Berg, R.; Varganov, A.; Vataga, E.; Vejcek, S., III; Velev, G.; Veramendi, G.; Vickey, T.; Vidal, R.; Vila, I.; Vilar, R.; Vittone, M.; Voirin, J.; Vollmer, B.; Vollrath, I.; Volobouev, I.; von der Mey, M.; Votava, M.; Wagner, R. G.; Wagner, R. L.; Wagner, W.; Wallace, N.; Walter, T.; Walters, A.; Wan, Z.; Wandersce, A.; Wang, M. J.; Wang, S. M.; Ward, B.; Waschke, S.; Waters, D.; Watts, T.; Weber, M.; Weems, L.; Wenzel, H.; Wester, W.; Whitehouse, B.; Wickenberg, W.; Wicklund, A. B.; Wicklund, E.; Wigmans, R.; Wike, C.; Wilkes, T.; Williams, H. H.; Wilson, P.; Winer, B. I.; Wittich, P.; Wolbers, S.; Wolter, M.; Wong, M.; Worcester, M.; Worland, R.; Worm, S.; Wright, T.; Wu, J.; Wu, X.; Wuethwein, F.; Wyatt, A.; Yagil, A.; Yamamoto, K.; Yamashita, T.; Yang, U. K.; Yao, W.; Yarema, R.; Yeh, G. P.; Yi, K.; Yocum, D.; Yoh, J.; Yoon, P.; Yorita, K.; Yoshida, T.; Yu, I.; Yu, S.; Yu, Z.; Yun, J. C.; Zalokar, M.; Zanzello, L.; Zanetti, A.; Zaw, I.; Zetti, F.; Zhou, J.; Zimmerman, T.; Zsenei, A.; Zucchelli, S.

CORPORATE SOURCE:

Univ. Florida, Gainesville, FL, 32611, USA

SOURCE: Los Alamos National Laboratory, Preprint Archive, High Energy Physics--Experiment (2003) 1-24,
arXiv:hep-ex/0310043, 20 Oct 2003
CODEN: LNHEFS
URL: <http://xxx.lanl.gov/pdf/hep-ex/0310043>

PUBLISHER: Los Alamos National Laboratory
DOCUMENT TYPE: Preprint
LANGUAGE: English

AB We present a measurement of the mass difference $m(Ds^+) - m(D^+)$, where both the Ds^+ and D^+ are reconstructed in the $\nu\mu\pi^+$ decay channel. This measurement uses 11.6 pb $^{-1}$ of data collected by CDF II using the new displaced-track trigger. The mass difference is found to be $m(Ds^+) - m(D^+) = 99.41 \pm 0.38 (\text{stat.}) \pm 0.21 (\text{syst.})$ MeV/c 2 .

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 19 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:881082 ZCAPLUS [Full-text](#)

DOCUMENT NUMBER: 140:118443

TITLE: Measurement of the mass difference $m(Ds^+) - m(D^+)$ at CDF II

AUTHOR(S): Acosta, D.; Affolder, T.; Ahn, M. H.; Akimoto, T.; Albrow, M. G.; Alcorn, B.; Alexander, C.; Allen, D.; Allspach, D.; Amaral, P.; Ambrose, D.; Amendolia, S. R.; Amidei, D.; Amundson, J.; Anastassov, A.; Anderson, J.; Anikeev, K.; Annovi, A.; Antos, J.; Aoki, M.; Apollinari, G.; Arguin, J.-F.; Arisawa, T.; Artikov, A.; Asakawa, T.; Ashmanskas, W.; Attal, A.; Avanzini, C.; Azfar, F.; Azzi-Bacchetta, P.; Babik, M.; Bacchetta, N.; Bachacou, H.; Badgett, W.; Bailey, S.; Bakken, J.; Barbaro-Galtieri, A.; Bardi, A.; Bari, M.; Barker, G.; Barnes, V. E.; Barnett, B. A.; Baroiant, S.; Barone, M.; Barsotti, E.; Basti, A.; Bauer, G.; Beckner, D.; Bedeschi, F.; Behari, S.; Belforte, S.; Bell, W. H.; Bellendir, G.; Bellettini, G.; Bellinger, J.; Benjamin, D.; Beretvas, A.; Berg, B.; Bhatti, A.; Binkley, M.; Bisello, D.; Bishai, M.; Blair, R. E.; Blocker, C.; Bloom, K.; Blumenfeld, B.; Bocci, A.; Bodek, A.; Bogdan, M.; Bolla, G.; Bolshov, A.; Booth, P. S. L.; Bortoletto, D.; Boudreau, J.; Bourov, S.; Bowden, M.; Box, D.; Bromberg, C.; Brown, W.; Brozovic, M.; Brubaker, E.; Buckley-Geer, L.; Budagov, J.; Budd, H. S.; Burkett, K.; Busetto, G.; Bussey, P.; Byon-Wagner, A.; Byrum, K. L.; Cabrera, S.; Calafiura, P.; Campanelli, M.; Campbell, M.; Canal, P.; Canepa, A.; Carithers, W.; Carlsmith, D.; Carosi, R.; Carrell, K.; Carter, H.; Caskey, W.; Castro, A.; Cauz, D.; Cerri, A.; Cerri, C.; Cerrito, L.; Chandler, J. T.; Chapman, J.; Chappa, S.; Chen, C.; Chen, Y. C.; Cheng, M. T.; Chertok, M.; Chiarelli, G.; Chirikov-Zorin, I.; Chlachidze, G.; Chleban, F.; Cho, I.; Cho, K.; Chokheli, D.; Chu, M. L.; Chung, J. Y.; Chung, W.-H.; Chung, Y. S.; Ciobanu, C. I.; Ciocci, M. A.; Cisko, S.; Clark, A. G.; Coca, M.; Coile, K.; Colijn, A. P.; Colombo, R.; Connolly, A.; Convery, M.; Conway, J.; Cooper, G.; Cordelli, M.; Cortiana, G.; Cranshaw, J.; Cudzewicz, R.; Culbertson, R.; Currat, C.; Cyr, D.; Dagenhart, D.; DalMonte, L.; DaRonco, S.; D'Auria, S.; Davila, R.; Dawson, J.; Dawson, T.; de Barbaro, P.; DeBaun, C.; De Cecco, S.;

Dell'Agnello, S.; Dell'Orso, M.; DeMaat, R.; Demar, P.; Demers, S.; Demortier, L.; Deninno, M.; De Pedis, D.; Derwent, P. F.; Derylo, G.; Devlin, T.; Dionisi, C.; Dittmann, J. R.; Doksus, P.; Dominguez, A.; Donati, S.; Donno, F.; D'Onofrio, M.; Dorigo, T.; Downing, R.; Drake, G.; Drennan, C.; Drollinger, V.; Dunietz, I.; Dyer, A.; Ebina, K.; Eddy, N.; Ely, R.; Engels, E., Jr.; Erbacher, R.; Erdmann, M.; Errede, D.; Errede, S.; Eusebi, R.; Fang, H.-C.; Farrington, S.; Feild, R. G.; Feindt, M.; Fernandez, J. P.; Ferretti, C.; Field, R. D.; Fiori, I.; Fischler, M.; Flanagan, G.; Flaughner, B.; Flores-Castillo, L. R.; Foland, A.; Forrester, S.; Foster, G. W.; Franklin, M.; Frisch, H.; Fromm, J.; Fujii, Y.; Furic, I.; Galeotti, S.; Galet, G.; Gallas, A.; Gallinaro, M.; Ganel, O.; Garcia, C.; Garcia-Sciveres, M.; Garfinkel, A. F.; Garwacki, M.; Garzoglio, G.; Gay, C.; Gerberich, H.; Gerdes, D. W.; Gerchtein, E.; Gerstenslager, J.; Giacchetti, L.; Giagu, S.; Giannetti, P.; Gibson, A.; Gillespie, G., Jr.; Gingu, C.; Ginsburg, C.; Giolo, K.; Giordani, M.; Glagolev, V.; Glenzinski, D.; Glossen, R.; Gold, M.; Goldschmidt, N.; Goldstein, D.; Goldstein, J.; Gomez, G.; Goncharov, M.; Gonzalez, H.; Gordon, S.; Gorelov, I.; Goshaw, A. T.; Gotra, Y.; Goulianos, K.; Grado, J.; Gregori, M.; Gresele, A.; Griffin, T.; Grim, G.; Grimm, C.; Gromoll, S.; Grosso-Pilcher, C.; Gu, C.; Guarino, V.; Guenther, M.; Guimaraes da Costa, J.; Haber, C.; Hahn, A.; Hahn, K.; Hahn, S. R.; Halkiadakis, E.; Hall, C.; Handler, R.; Haney, M.; Hao, W.; Happacher, F.; Hara, K.; Hare, M.; Harr, R. F.; Harrington, J.; Harris, R. M.; Hartmann, F.; Hatakeyama, K.; Hauser, J.; Hawke, T.; Hays, C.; Heider, E.; Heinemann, B.; Heinrich, J.; Heiss, A.; Hennecke, M.; Herber, R.; Herndon, M.; Herren, M.; Hicks, D.; Hill, C.; Hirschbuehl, D.; Hocker, A.; Hoff, J.; Hoffman, K. D.; Hoftiezer, J.; Holloway, A.; Holloway, L.; Holm, S.; Humbert, J.; Huston, J.; Ikado, K.; Incandela, J.; Introzzi, G.; Iori, M.; Ishizawa, I.; Issever, C.; Ivanov, A.; Iwata, Y.; Iyutin, B.; James, E.; Jang, D.; Jarrell, J.; Jeans, D.; Jensen, H.; Jetton, R.; Johnson, M.; Jones, M.; Jones, T.; Jun, S. Y.; Junk, T.; Kallenbach, J.; Kamon, T.; Kang, J.; Karagoz Unel, M.; Karchin, P. E.; Kartal, S.; Kasha, H.; Kasten, M.; Kato, Y.; Kemp, Y.; Kennedy, R. D.; Kephart, K.; Kephart, R.; Khazins, D.; Khotilovich, V.; Kilminster, B.; Kim, B. J.; Kim, D. H.; Kim, H. S.; Kim, J.; Kim, M. J.; Kim, M. S.; Kim, S. B.; Kim, S. H.; Kim, T. H.; Kim, Y. K.; King, B. T.; Kirby, M.; Kirk, M.; Kirsch, L.; Klein, R.; Klimenko, S.; Knapp, M.; Knoblauch, D.; Knuteson, B.; Kobayashi, H.; Koehn, P.; Kondo, K.; Kong, D. J.; Konigsberg, J.; Kononenko, W.; Kordas, K.; Korn, A.; Korytov, A.; Kotelnikov, K.; Kotwal, A.; Kovalev, A.; Kowalkowski, J.; Kraus, J.; Kravchenko, I.; Kreymer, A.; Kroll, J.; Kruse, M.; Krutelyov, V.; Kuhlmann, S. E.; Kumar, A.; Kuznetsova, N.; Laasanen, A. T.; Lai, S.; Lami, S.; Lammel, S.; Lamore, D.; Lancaster, J.; Lancaster, M.; Lander, R.; Lanfranco, G.; Lannon, K.; Lath, A.; Latino, G.; Lauhakangas, R.; Lazzizzera, I.;

Le, Y.; Lecompte, T.; Lee, J.; Lee, J.; Lee, K.; Lee, S. W.; Lei, C. M.; Leininger, M.; Leonardi, G. L.; Leonardo, N.; Leone, S.; Levshina, T.; Lewis, F.; Lewis, J. D.; Li, K.; Lin, C. S.; Lindgren, M.; Liss, T. M.; Litvintsev, D. O.; Liu, T.; Liu, Y.; Lobban, O.; Lockyer, N. S.; Loginov, A.; Loken, J.; Loreti, M.; Loskot, J.; Loverre, P. F.; Lucchesi, D.; Lukens, P.; Lutz, P.; Lyons, L.; Lys, J.; MacNerland, J.; MacQueen, D.; Madorsky, A.; Madrak, R.; Maeshima, K.; Maksimovic, P.; Malferrari, L.; Mammini, P.; Manca, G.; Mandrichenko, I.; Manea, C.; Marginean, R.; Marrafinio, J.; Martin, A.; Martin, M.; Martin, V.; Martinez, M.; Maruyama, T.; Matsunaga, H.; Mayer, J.; Mayers, G. M.; Mazzanti, P.; McFarland, K. S.; McGivern, D.; McIntyre, P. M.; McNamara, P.; McNulty, R.; Menzemer, S.; Menzione, A.; Merkel, P.; Mesropian, C.; Messina, A.; Meyer, A.; Miao, T.; Michael, N.; Miller, J. S.; Miller, L.; Miller, R.; Miquel, R.; Miscetti, S.; Mitselmakher, G.; Miyamoto, A.; Miyazaki, Y.; Mizicko, D.; Moccia, S.; Moggi, A.; Montero, S.; Moore, R.; Moore, T.; Morris, L.; Morsani, F.; Moulik, T.; Mukherjee, A.; Mulhearn, M.; Muller, T.; Mumford, R.; Munar, A.; Murat, P.; Murgia, S.; Nachtman, J.; Nagaslaev, V.; Nahn, S.; Nakamura, I.; Nakano, I.; Napier, A.; Napor, R.; Necula, V.; Nelson, C.; Nelson, T.; Neu, C.; Neubauer, M. S.; Neuberger, D.; Newby, W.; Newcomer, F. M.; Newman-Holmes, C.; Niell, F.; Nielsen, J.; Nicollerat, A.-S.; Nigmanov, T.; Niu, H.; Nodulman, L.; Noe, W., Jr.; Oesterberg, K.; Ogawa, T.; Oh, S.; Oh, Y. D.; Ohl, K.; Ohsugi, T.; Oishi, R.; Okuswa, T.; Oldeman, R.; Orava, R.; Orejudos, W.; Orr, S.; Pagani, G.; Pagliarone, C.; Palmonari, F.; Ramos, I.; Panacek, S.; Pantano, D.; Paoletti, R.; Papadimitriou, V.; Pasetes, R.; Pashapour, S.; Passuello, D.; Paterno, M.; Patrick, J.; Pauletta, G.; Paulini, M.; Pauly, T.; Paus, C.; Pavlicek, V.; Pavlon, S.; Pellett, D.; Penzo, A.; Perington, B.; Petragnani, G.; Petravick, D.; Phillips, T. J.; Photos, F.; Piacentino, G.; Picciolo, C.; Piccoli, L.; Piedra, J.; Pitts, K. T.; Plunkett, R.; Pompos, A.; Pondrom, L.; Pope, G.; Poukhov, O.; Prakoshyn, F.; Pratt, T.; Profeti, A.; Pronko, A.; Proudfoot, J.; Punzi, G.; Rademacker, J.; Raffaelli, F.; Rakitine, A.; Rappoccio, S.; Ratnikov, F.; Rauch, J.; Ray, H.; Rechenmacher, R.; Reia, S.; Reichold, A.; Rekovic, V.; Renton, P.; Rescigno, M.; Rimondi, F.; Rinnert, K.; Ristori, L.; Riveline, M.; Rivetta, D.; Robertson, W. J.; Robson, A.; Rodrigo, T.; Rolli, S.; Roman, M.; Rosenberg, S.; Rosenson, L.; Roser, R.; Rossin, R.; Rott, C.; Ruiz, A.; Russ, J.; Ryan, D.; Saarikko, H.; Sabik, S.; Sadler, L.; Safonov, A.; St. Denis, R.; Sakumoto, W. K.; Saltzberg, D.; Sanchez, C.; Sanders, H.; Sanders, R.; Sandrew, M.; Sansoni, A.; Santi, L.; Sarkar, S.; Sarraj, H.; Sarraj, J.; Sato, H.; Savard, P.; Schemitz, P.; Schlabach, P.; Schmidt, E. E.; Schmidt, J.; Schmidt, M. P.; Schmitt, M.; Schmitt, R.; Schmitz, M.; Schofield, G.; Schuh, K.; Schultz, K.; Scodellaro, L.; Scott, L.; Scribano, A.; Scuri, F.; Sedov, A.; Segler, S.; Seidel, S.; Seiya, Y.; Semenov, A.;

Semeria, F.; Sexton-Kennedy, L.; Sfiligoi, I.; Shallenberger, J.; Shapiro, M. D.; Shaw, T.; Shears, T.; Shenai, A.; Shepard, P. F.; Shimojima, M.; Schochet, M.; Shon, Y.; Shoun, M.; Sidoti, A.; Siegrist, J.; Sieh, C.; Siket, M.; Sill, A.; Silva, R.; Simaitis, V.; Sinervo, P.; Sirotenko, I.; Sisakyan, A.; Skiba, A.; Slaughter, A. J.; Sliwa, K.; Smith, J.; Snider, F. D.; Snihur, R.; Somalwar, V.; Spalding, J.; Spezziga, M.; Spiegel, L.; Spinella, F.; Spiropulu, M.; Stadie, H.; Stanek, R.; Stanfield, N.; Stelzer, B.; Stelzer-Chilton, O.; Strolgas, J.; Stuart, D.; Stuermer, W.; Sukhanov, A.; Sumorok, K.; Sun, H.; Suzuki, T.; Syu, J.; Szymulanski, A.; Taffard, A.; Takach, S. F.; Takano, H.; Takashima, R.; Takeuchi, Y.; Takikawa, K.; Tamburello, P.; Tanaka, M.; Tanaka, R.; Tang, D.; Tanimoto, N.; Tannenbaum, B.; Tapprogge, S.; Taylor, R. D.; Teafae, G.; Tecchio, M.; Teng, P. K.; Terashi, K.; Terentiev, T.; Tesarek, R. J.; Tether, S.; Thom, J.; Thomas, A.; Thompson, A. S.; Thomson, E.; Thurman-Keup, R.; Timm, S.; Tipton, P.; Tkaczyk, S.; Toback, D.; Tollefson, K.; Tonelli, D.; Tonnesmann, M.; Toretta, D.; Trimby, C.; Trischuk, W.; Trumbo, J.; Tseng, J.; Tsuchiya, R.; Tsuno, S.; Tsybychev, D.; Turini, N.; Turner, M.; Ukegawa, F.; Unverhau, T.; Uozumi, S.; Usynin, D.; Vacavant, L.; Vaiculis, T.; Van Berg, R.; Varganov, A.; Vataga, E.; Vejcek, S., III; Velez, G.; Veramendi, G.; Vickey, T.; Vidal, R.; Vila, I.; Vilar, R.; Vittone, M.; Voisin, J.; Vollmer, B.; Vollrath, I.; Volobouev, I.; von der Mey, M.; Votava, M.; Wagner, R. G.; Wagner, R. L.; Wagner, W.; Wallace, N.; Walter, T.; Walters, A.; Wan, Z.; Wandersee, A.; Wang, M. J.; Wang, S. M.; Ward, B.; Waschke, S.; Waters, D.; Watts, T.; Weber, M.; Weems, L.; Wenzel, H.; Wester, W.; Whitehouse, B.; Wickenberg, W.; Wicklund, A. B.; Wicklund, E.; Wigmans, R.; Wike, C.; Wilkes, T.; Williams, H. H.; Wilson, P.; Winer, B. L.; Wittich, P.; Wolbers, S.; Wolter, M.; Wong, M.; Worcester, M.; Worland, R.; Worm, S.; Wright, T.; Wu, J.; Wu, X.; Wuethrich, F.; Wyatt, A.; Yagil, A.; Yamamoto, K.; Yamashita, T.; Yang, U. K.; Yao, W.; Yarma, R.; Yeh, G. P.; Yi, K.; Yocum, D.; Yoh, J.; Yoon, P.; Yorita, K.; Yoshida, T.; Yu, I.; Yu, S.; Yu, Z.; Yun, J. C.; Zalokar, M.; Zanello, L.; Zanetti, A.; Zaw, I.; Zetti, F.; Zhou, J.; Zimmerman, T.; Zzenei, A.; Zucchelli, S.

CORPORATE SOURCE:

SOURCE:

Univ. Florida, Gainesville, FL, 32611, USA
Physical Review D: Particles and Fields (2003), 68(7),
072004/1-072004/11

CODEN: PRVDAQ; ISSN: 0556-2821

PUBLISHER:

DOCUMENT TYPE:

LANGUAGE:

American Physical Society

Journal

English

AB We present a measurement of the mass difference $m(Ds^+)-m(D^+)$, where both the Ds^+ and D^+ are reconstructed in the $\phi\pi^+$ decay channel. This measurement uses 11.6 pb⁻¹ of data collected by CDF II using the new displaced-track trigger. The mass difference is $m(Ds^+)-m(D^+)=99.41\pm0.38(\text{stat})\pm0.21(\text{syst})\text{ MeV}/c^2$.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2001:409809 ZCAPLUS Full-text
 DOCUMENT NUMBER: 136:91794
 TITLE: New measurement of parity violation in elastic electron-proton scattering and implications for strange form factors
 AUTHOR(S): Aniol, K. A.; Armstrong, D. S.; Averett, T.; Baylac, M.; Burtin, E.; Calarco, J.; Cates, G. D.; Cavata, C.; Chai, Z.; Chang, C. C.; Chen, J.-P.; Chudakov, E.; Cissbani, E.; Coman, M.; Dale, D.; Deur, A.; Djawotho, P.; Epstein, M. B.; Escoffier, S.; Ewell, L.; Falletto, N.; Finn, J. M.; Fleck, A.; Frois, B.; Frullani, S.; Gao, J.; Garibaldi, F.; Gasparian, A.; Gerstner, G. M.; Gilman, R.; Glamazdin, A.; Gomez, J.; Gorbenko, V.; Hansen, O.; Hersman, F.; Higinbotham, D. W.; Holmes, R.; Holtrop, M.; Humensky, B.; Incerti, S.; Iodice, M.; de Jager, C. W.; Jardiillier, J.; Jiang, X.; Jones, M. K.; Jorda, J.; Jutier, C.; Kahl, W.; Kelly, J. J.; Kim, D. H.; Kim, M.-J.; Kim, M. S.; Kominis, I.; Kooijman, E.; Kramer, K.; Kumar, K. S.; Kuss, M.; LeRose, J.; De Leo, R.; Leuschner, M.; Lhuillier, D.; Liang, M.; Liyanage, N.; Lourie, R.; Madey, R.; Malov, S.; Margaziotis, D. J.; Marie, F.; Markowitz, P.; Martino, J.; Mastromarino, P.; McCormick, K.; McIntyre, J.; Meiziani, Z.-E.; Michaels, R.; Milbrath, B.; Miller, G. W.; Mitchell, J.; Morand, L.; Neyret, D.; Petratos, G. G.; Pomatsalyuk, R.; Price, J. S.; Prout, D.; Pussieux, T.; Quemener, G.; Ransome, R. D.; Relyea, D.; Roblin, Y.; Roche, J.; Rutledge, G. A.; Rutt, P. M.; Rvachev, M.; Sabatie, F.; Saha, A.; Souder, P. A.; Spradlin, M.; Strauch, S.; Suleiman, R.; Templon, J.; Teresawa, T.; Thompson, J.; Tieulent, R.; Todor, L.; Tonguc, B. T.; Ulmer, P. E.; Urciuoli, G. M.; Vlahovic, B.; Wijesooriya, K.; Wilson, R.; Wojtsekhowski, B.; Woo, R.; Xu, W.; Younus, I.; Zhang, C.
 CORPORATE SOURCE: California State University-Los Angeles, Los Angeles, CA, 90032, USA
 SOURCE: Physics Letters B (2001), 509(3,4), 211-216
 CODEN: PYLBAJ; ISSN: 0370-2693
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB We have measured the parity-violating electroweak asymmetry in the elastic scattering of polarized electrons from the proton. The result is $A = -15.05 \pm 0.98$ (stat) ± 0.56 (syst) ppm at the kinematic point $\langle \theta_{lab} \rangle = 12.3^\circ$ and $\langle Q^2 \rangle = 0.477$ (GeV/c)². Both errors are a factor of two smaller than those of the result reported previously. The value for the strange form factor extracted from the data is $(G_S + 0.392 G_M) = 0.025 \pm 0.020 \pm 0.014$, where the first error is exptl. and the second arises from the uncertainties in electromagnetic form factors. This measurement is the first fixed-target parity violation experiment that used either a "strained" GaAs photocathode to produce highly polarized electrons or a Compton polarimeter to continuously monitor the electron beam polarization.
 REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L35 ANSWER 21 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:389470 ZCAPLUS Full-text
 DOCUMENT NUMBER: 133:64700

TITLE: New measurement of parity violation in elastic electron-proton scattering and implications for strange form factors

AUTHOR(S): Aniol, K. A.; Armstrong, D. S.; Averett, T.; Baylac, M.; Burtin, E.; Calarco, J.; Cates, G. D.; Cavata, C.; Chai, Z.; Chang, C. C.; Chen, J.-P.; Chudakov, E.; Cisbani, E.; Coman, M.; Dale, D.; Deur, A.; Djawotho, P.; Epstein, M. B.; Escoffier, S.; Ewell, L.; Falletto, N.; Finn, J. M.; Fleck, A.; Frois, B.; Frullani, S.; Gao, J.; Garibaldi, F.; Gasparian, A.; Gerstner, G. M.; Gilman, R.; Glamazdin, A.; Gomez, J.; Gorbenko, V.; Hansen, O.; Hersman, F.; Higinbotham, D. W.; Holmes, R.; Holtrop, M.; Humensky, B.; Incerti, S.; Iodice, M.; de Jager, C. W.; Jardillier, J.; Jiang, X.; Jones, M. K.; Jorda, J.; Jutier, C.; Kahl, W.; Kelly, J. J.; Kim, D. H.; Kim, M.-J.; Kim, M. S.; Kominis, I.; Kooijman, E.; Kramer, K.; Kumar, K. S.; Kuss, M.; LeRose, J.; De Leo, R.; Leuschner, M.; Lhuillier, D.; Liang, M.; Liyanage, N.; Lourie, R.; Madey, R.; Malov, S.; Margaziotis, D. J.; Marie, F.; Markowitz, P.; Martino, J.; Mastroianni, P.; McCormick, K.; McIntyre, J.; Mezziani, Z.-E.; Michaels, R.; Milbrath, B.; Miller, G. W.; Mitchell, J.; Morand, L.; Neyret, D.; Petratos, G. G.; Pomatsalyuk, R.; Price, J. S.; Prout, D.; Pussieux, T.; Quemener, G.; Ransome, R. D.; Relyea, D.; Roblin, Y.; Roche, J.; Rutledge, G. A.; Rutt, P. M.; Ryachev, M.; Sabatie, F.; Saha, A.; Souder, P. A.; Spradlin, M.; Strauch, S.; Suleiman, R.; Templon, J.; Teresawa, T.; Thompson, J.; Tieulent, R.; Todor, L.; Tonguc, B. T.; Ulmer, P. E.; Urciuoli, G. M.; Vlahovic, B.; Wijesooriya, K.; Wilson, R.; Wojtsekhowski, B.; Woo, R.; Xu, W.; Younus, I.; Zhang, C.

CORPORATE SOURCE: HAPPEX Collaboration, California State Univ., Los Angeles, CA, 90032, USA

SOURCE: Los Alamos National Laboratory, Preprint Archive, Nuclear Experiment (2000) 1-6, arXiv:nucl-ex/0006002, 6 Jun 2000
CODEN: LNNEFO
URL: <http://xxx.lanl.gov/pdf/nucl-ex/0006002>

PUBLISHER: Los Alamos National Laboratory

DOCUMENT TYPE: Preprint

LANGUAGE: English

AB We have measured the parity-violating electroweak asymmetry in the elastic scattering of polarized electrons from the proton. The result is $A = 14.60 \pm 0.94 (\text{stat}) \pm 0.54 (\text{syst})$ ppm at the kinematic point $\langle \theta_{\text{lab}} \rangle = 12.3^\circ$ and $\langle Q^2 \rangle = 0.477 \text{ (GeV/c)}^2$. The measurement implies that the value for the strange form factor ($G_S + 0.392 G_M / \mu_p$) = $0.091 \pm 0.054 \pm 0.039$, where the first error is exptl. and the second arises from the uncertainties in electromagnetic form factors. This measurement is the first fixed-target parity violation experiment that used either a "strained" GaAs photocathode to produce highly polarized electrons or a Compton polarimeter to continuously monitor the electron beam polarization.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 22 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:584382 ZCAPLUS Full-text

DOCUMENT NUMBER: 117:184382

10/576653

ORIGINAL REFERENCE NO.: 117:31597a,31600a
TITLE: Cardiotoxicity of three anthracycline antitumor antibiotics
AUTHOR(S): Li, Xiangduan; Shi, Anguo; Fu, Wenjun; Cheng, Weiju; Xu, Wenyi; Pan, Xianxin
CORPORATE SOURCE: Shanghai Inst. Pharm. Ind., Shanghai, 200437, Peop. Rep. China
SOURCE: Zhongguo Yiyao Gongye Zazhi (1992), 23(3), 116-19
CODEN: ZYGZEA; ISSN: 1001-8255
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
AB The cardiotoxicity of daunorubicin (DNR), adriamycin (ADM), and aclacinomycin-B (ACM-B) was investigated in rabbits by measuring ECG, systolic time interval, and myocardial pathomorphol. changes. ADM and ACM-B caused arrhythmia and all 3 drugs damaged the cardiac function and myocardial histol.

L35 ANSWER 23 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:521660 ZCAPLUS [Full-text](#)
DOCUMENT NUMBER: 107:121660
ORIGINAL REFERENCE NO.: 107:19599a,19602a
TITLE: Light scattering in a dilute microemulsion. II. Radius dependence of interactions
AUTHOR(S): Dozier, William D.; Kim, Mahn Won; Klein, Rudolf
CORPORATE SOURCE: Exxon Res. and Eng. Co., Annandale, NJ, 08801, USA
SOURCE: Journal of Chemical Physics (1987), 87(2), 1455-6
CODEN: JCPSA6; ISSN: 0021-9606
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The interactions between microemulsion droplets was studied on the same type microemulsion, having different weight ratios of surfactant/H₂O and hence different drop radii. The investigated system was AOT-H₂O-decane, with 37, 45, and 55 Å radii of droplets. The mutual diffusion coefficient and the static structure factor were determined as functions of both droplet radius and volume fraction of the minor component. The results agree with theor. prediction.

L35 ANSWER 24 OF 31 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:231037 ZCAPLUS [Full-text](#)
DOCUMENT NUMBER: 104:231037
ORIGINAL REFERENCE NO.: 104:36551a,36554a
TITLE: Light scattering measurements in a dilute microemulsion
AUTHOR(S): Kim, Mahn Won; Dozier, William D.; Klein, Rudolf
CORPORATE SOURCE: Exxon Res. Eng., Annandale, NJ, 08801, USA
SOURCE: Journal of Chemical Physics (1986), 84(10), 5919-21
CODEN: JCPSA6; ISSN: 0021-9606
DOCUMENT TYPE: Journal
LANGUAGE: English

AB There was measured the mutual diffusion coefficient and static light scattering intensity at small angle of a water-in-oil microemulsion at low (0.005-0.04) minor component volume fraction. The system studied was AOT/water/decaene at 25°. A linear dependence was on volume fraction for both quantities, with viral coeffs. of -17 and -11, resp., for the static structure factor and mutual diffusion coefficient Using available expressions for these coeffs. as a function of the parameters of a model potential consisting of an attractive square well and a hard core, these results are in agreement with those previously obtained by neutron scattering.

L35 ANSWER 25 OF 31 MEDLINE on STN DUPLICATE 16
 ACCESSION NUMBER: 1987079826 MEDLINE Full-text
 DOCUMENT NUMBER: PubMed ID: 3098513
 TITLE: T lymphocyte subpopulations in chronic renal failure.
 AUTHOR: Hou J S; Ma J M; Feng H F; Zuo J N; Cheng W Y; Zhu X;
 Huang J W; Xu W Z; Gu H D; Zhu B F
 SOURCE: Chinese medical journal, (1986 Apr) Vol. 99, No. 4, pp.
 321-2.
 Journal code: 7513795. ISSN: 0366-6999.
 PUB. COUNTRY: China
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 198702
 ENTRY DATE: Entered STN: 2 Mar 1990
 Last Updated on STN: 2 Mar 1990
 Entered Medline: 10 Feb 1987
 CONTROLLED TERM: Check Tags: Female; Male
 Adolescent
 Adult
 Humans
 *Kidney Failure, Chronic: IM, immunology
 Killer Cells: IM, immunology
 Leukocyte Count
 Middle Aged
 *T-Lymphocytes: CL, classification

L35 ANSWER 26 OF 31 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on
 STN
 ACCESSION NUMBER: 1993:458286 BIOSIS Full-text
 DOCUMENT NUMBER: PREV199396103186
 TITLE: Studies on the chemical constituents of Rosa laevigata
 Michx.
 AUTHOR(S): Gao, Ying [Reprint author]; Cheng, Weiming [Reprint
 author]; Li, Guangyi [Reprint author]; Xu, Weikun; Meng,
 Lisan
 CORPORATE SOURCE: Inst. Materia Medica, Chinese Acad. Med. Sci., Beijing
 100060, China
 SOURCE: China Journal of Chinese Materia Medica, (1993) Vol. 18,
 No. 7, pp. 426-427, 447.
 DOCUMENT TYPE: Article
 LANGUAGE: Chinese
 ENTRY DATE: Entered STN: 5 Oct 1993
 Last Updated on STN: 5 Oct 1993
 ABSTRACT: Six compounds were isolated from Rosa laevigata. Five of them were
 obtained from the ethanolic extract and identified as 2-alpha,3-beta,19-
 alpha,23-tetrahydroxyurs-12-en-28-oic acid, 2-alpha,3-alpha,19-alpha,23-
 tetrahydroxyurs-12-en-28-oic acid, euscaphic acid, beta-sitosterol and
 daucosterol. The other one was obtained from the acetate of emulsive layer of
 the petroleum ether and elucidated as 2-alpha,3-beta-dihydrolup-28-methyl ester
 diacetate.
 CONCEPT CODE: Biochemistry studies - Lipids 10066
 Pharmacology - General 22002

Plant physiology - Chemical constituents 51522
 Pharmacognosy and pharmaceutical botany 54000

INDEX TERMS: Major Concepts
 Biochemistry and Molecular Biophysics; Pharmacognosy
 (Pharmacology); Pharmacology

INDEX TERMS: Miscellaneous Descriptors
 AMYGDALIN; BETULIC ACID; MEDICINAL PLANT; STEARIC ACID

ORGANISM: Classifier
 Araliaceae 25590
 Super Taxa
 Dicotyledones; Angiospermae; Spermatophyta; Plantae
 Organism Name
 Acanthopanax senticosus
 Taxa Notes
 Angiosperms, Dicots, Plants, Spermatophytes, Vascular
 Plants

ORGANISM: Classifier
 Rosaceae 26675
 Super Taxa
 Dicotyledones; Angiospermae; Spermatophyta; Plantae
 Organism Name
 Rosaceae
 Taxa Notes
 Angiosperms, Dicots, Plants, Spermatophytes, Vascular
 Plants

L35 ANSWER 27 OF 31 WPIX COPYRIGHT 2008 THOMSON REUTERS on STN
 2008-E86548 [34] WPIX [Full-text](#)
 ACCESSION NUMBER:
 DOC. NO. NON-CPI: N2008-383176 [34]
 TITLE: Multi-read port register documentation level drive bit
 unit circuit, has output terminal connected with read
 port unit, where size of inverter is increased along
 direction from memory bank core unit to read port unit
 U14
 DERWENT CLASS:
 INVENTOR: CHEN J; CHEN N; DONG L; HE P; HE X; LE D; LI S; LIU T;
 LIU Z; MA J; SUN Y; TANG S; XU W; ZHANG M; ZHAO Z
 PATENT ASSIGNEE: (UYCH-N) UNIV CHINESE PEOPLES LIBERATION ARMY NAT
 COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND DATE	WEEK	LA	PG	MAIN IPC
CN 101110261	A 20080123	(200834)*	ZH	9[4]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
CN 101110261	A	CN 2007-10035331	20070710

PRIORITY APPLN. INFO: CN 2007-10035331 20070710
 INT. PATENT CLASSIF.:
 IPC ORIGINAL: G11C0007-00 [I,C]; G11C0007-22 [I,A]
 BASIC ABSTRACT:

CN 101110261 A UPAB: 20080528
 NOVELTY - The circuit has p-type metal oxide semiconductor (PMOS) tubes
 (P1, P2) and n-type MOS (NMOS) tubes (N1, N2, N3), which form tri-state memory
 bank core unit, read port unit, write port unit and inverter chain. The write
 port unit is connected with the memory bank core unit, where the inverter has

different sizes. The input terminal of inverter chain is connected with memory bank core unit. An output terminal is connected with read port unit. The size of inverter is increased steadily and progressively along the direction from memory bank core unit to read port unit in inverter chain.

USE - Multi-read port register documentation level drive bit unit circuit.

ADVANTAGE - The multi-read port register documentation level drive bit unit circuit reduces the drive load of core unit, to reduce the acreage of core unit, and confirms that the data is read correctly.

DESCRIPTION OF DRAWINGS - The drawing shows a circuit block diagram of a multi-read port register documentation level drive bit unit circuit. (Drawing includes non-English language text)

P-type metal oxide semiconductor tube (P1, P2)

N-type metal oxide semiconductor tube (N1-N3) MANUAL CODE:

EPI: U14-A07; U14-A07C; U14-A08B1

L35 ANSWER 28 OF 31 WPIX COPYRIGHT 2008 THOMSON REUTERS on STN
 ACCESSION NUMBER: 2008-E52116 [31] WPIX Full-text
 DOC. NO. NON-CPI: N2008-353600 [31]
 TITLE: Sub-word parallel integer multiplier, has data pre-process module provided for inputting with multiplicand and multiplier factor and control signal, and correction selection module fixed for selecting and uniting correction values
 DERWENT CLASS: T01
 INVENTOR: CHEN J; CHEN N; DONG L; HE P; HE X; LE D; LI S; LIU T; MA J; SUN Y; XU W; YU R; ZHANG M; ZHAO Z; ZHENG D
 PATENT ASSIGNEE: (UYPL-N) UNIV PLA NAT DEFENCE SCI & TECHNOLOGY
 COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
CN 101110016	A	20080123	(200831)*	ZH	13[4]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
CN 101110016	A	CN 2007-10035651	20070829

PRIORITY APPLN. INFO: CN 2007-10035651 20070829

INT. PATENT CLASSIF.:

IPC ORIGINAL: G06F0007-48 [I,C]; G06F0007-53 [I,A]

BASIC ABSTRACT:

CN 101110016 A UPAB: 20080514

NOVELTY - The multiplier has a data pre-process module provided for inputting with a multiplicand and multiplier factor and control signal, and expanding the multiplicand and multiplier factor. A correction selection module is fixed for selecting and uniting correction values. Four partition generation modules are respectively placed to generate a nine partition products of two low and two high bit multiplication. A partition product compression tree module is equipped for compressing partition product generated by partition product generation module and uniting correction value.

USE - Sub-word parallel integer multiplier.

ADVANTAGE - The multiplier has simple configuration, simplified arithmetic and actualization. The multiplier reduces the delay of the partition product compression unit, and improves performance of the multiplier.

DESCRIPTION OF DRAWINGS - The drawing shows a block diagram of a sub-word parallel integer multiplier. '(Drawing includes non-English language text)'
 MANUAL CODE: EPI: T01-E01B

L35 ANSWER 29 OF 31 WPIX COPYRIGHT 2008 THOMSON REUTERS ON STN
 ACCESSION NUMBER: 2008-C18525 [16] WPIX Full-text
 DOC. NO. CPI: C2008-062582 [16]
 TITLE: New azepinoindole compounds are farnesoid X receptor inhibitors useful for the treatment of e.g. hyperlipidemia, dyslipidemia, atherosclerosis, syndrome X, diabetes mellitus, hyperglycemia, cholestasis and obesity
 B02; B05
 DERWENT CLASS:
 INVENTOR: BAIK T; BUHR C A; BUSCH B B; CHAN D S; FLATT B T; GU X H; JAMMALAMADAKA V; KHOURY R G; LARA K; MA S; MARTIN R; MOHAN R; NUSS J M; PARKS J J; BUHR C; BUSCH B; CHAN D; FLATT B; GU X; KHOURY R; NUSS J; PARKS J; WANG L; WANG T; WU J; XU W; YEUNG B
 (EXEL-N) EXELIXIS INC
 PATENT ASSIGNEE:
 COUNTRY COUNT: 117

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2007070796	A1	20070621	(200816)*	EN	244[0]	
EP 1963331	A1	20080903	(200858)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2007070796	A1	WO 2006-US61928	20061212
EP 1963331	A1	EP 2006-846570	20061212
EP 1963331	A1	PCT Application	WO 2006-US61928 20061212

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1963331	A1 Based on	WO 2007070796 A

PRIORITY APPLN. INFO: US 2005-750679P 20051215
 US 2005-750634P 20051215

INT. PATENT CLASSIF.:
 IPC ORIGINAL: A61K0031-407 [I,A]; A61K0031-407 [I,C]; A61K0031-407 [I,C]; A61P0003-00 [I,A]; A61P0003-00 [I,C]; A61P0003-00 [I,C]; C07D0487-00 [I,C]; C07D0487-00 [I,C]; C07D0487-04 [I,A]

ECLA: C07D0487-04+223B+209B

BASIC ABSTRACT:

WO 2007070796 A1 UPAB: 20080306
 NOVELTY - Azepinoindole compounds (I) are new.
 DETAILED DESCRIPTION - Azepinoindole compounds of formula (I) are new.
 R1 = -C(J)R11, -C(J)OR11 or -C(J)N(R10)(R11);
 J = direct bond, O or NR10;
 n = 0-4;
 R3 = H, -C(O)R9 or CON(R11)(R12);
 R6, R7 = (cyclo)alkyl or cycloalkylalkyl (both optionally substituted);

R8 = alkenyl, alkynyl, (cyclo)alkyl, cycloalkylalkyl, heterocyclyl(alkyl), (hetero)aryl, (hetero)aralkyl (all optionally substituted), OH, halo(alkyl), haloalkoxy, -OC(O)N(R15)(R16), -OC(O)R11 or -OR20;

R9 = alkenyl, alkynyl, (cyclo)alkyl, cycloalkylalkyl, (hetero)aryl, (hetero)aralkyl, heterocyclylalkyl, heterocyclyl (all optionally substituted), OR10 or N(R12)(R13);

R10 = alkenyl, alkynyl, (cyclo)alkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, (hetero)aryl, (hetero)aralkyl (all optionally substituted) or H;

R11 = T, H, -OR14 or -N(R15)(R16);

T = alkenyl, alkynyl, (cyclo)alkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, (hetero)aryl or (hetero)aralkyl (all optionally substituted); either

R12, R13, R18, R20, R11, R25, R26 = T or H; or

NR12R13, NR20R21 = heterocyclyl or heteroaryl (both optionally substituted); either

R10-R13 = T or H; or

R10R11R12R13 = heterocyclic ring or heteroaryl ring (both optionally substituted); either

R14-R16 = H, -OR18, -SR18, -N(R20)(R21) or T; or

NR15R16 = heterocyclyl ring or heteroaryl ring (both optionally substituted);

R17 = alkyl, alkenyl, alkynyl (optionally substituted) or H;

R19 = alkylene or direct bond;

R22 = H, T, -R19-OR23, -R19-N(R23)(R24), -R19-C(J)R23, -R19-C(J)OR23 or -R19-C(J)N(R23)(R24); either

R23, R24 = H, T, -R19-OR25, -R19-N(R25)(R26), -R19-C(J)R25, -R19-C(J)OR25 or -R19-C(J)N(R25)(R26); or

NR23R24 = heterocyclyl or heteroaryl (both optionally substituted)

(where R21-R26 is substituted by Q1) either

Q1 = halo, pseudohalo, OH, oxo, thia, nitrile, MO2, formyl, mercapto, NH2, hydroxyalkyl, hydroxyalkylaryloxy, hydroxyaryl, hydroxyalkylaryl, hydroxycarbonyl, hydroxycarbonylalkyl, (halo)alkyl, polyhaloalkyl, (di)aminoalkyl, alkenyl containing 1-2 double bonds, alkynyl containing 1-2 triple bonds, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, (di)aryl, hydroxyaryl, alkylaryl, heteroaryl, aralkyl, aralkenyl, aralkynyl, alkylaralkyl, heteroarylalkyl, trialkylsilyl, dialkylarylsilyl, alkylidiarylsilyl, triarylsilyl, alkylidene, arylalkylidene, alkylcarbonyl, alkylarylcarbonyl, arylcarbonyl, heterocyclylcarbonyl, heteroarylcarbonyl, heteroarylalkoxycarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylaryloxy, aryloxy carbonyl, aryloxy carbonylalkyl, heterocyclylcarbonylalkylaryl, aralkoxycarbonyl, aralkoxycarbonylalkyl, arylcarbonylalkyl, aminocarbonyl, (di)alkylaminocarbonyl, (di)arylaminocarbonyl, arylalkylaminocarbonyl, (halo)alkoxy, alkoxylaryloxy, alkylaryloxy, (di)aryloxy, alkylaryloxyalkyl, alkylidiaryloxy, perfluoroalkoxy, alkynyl, alkynyl, aryloxyalkoxy, aralkoxyaryloxy, alkylarylcycloalkoxy, heterocycloxy, alkoxylalkyl, alkoxylalkoxyalkyl, alkylheteroaryloxy, alkylcycloalkoxy, cycloalkoxy, heterocyclioxy, aralkoxy, haloaryloxy, heteroaryloxy, alkylheteroaryloxy, alkoxycarbonylheterocycloxy, alkylcarbonylaryloxy, alkylcarbonyloxy, arylcarbonyloxy, aralkylcarbonyloxy, alkoxycarbonyloxy, aryloxy carbonyloxy, alkoxylaryloxy, aralkoxycarbonyloxy, ureido, alkylureido, arylureido, NH2, aminoalkyl, (di)alkylaminoalkyl, (di)arylaminocarbonyl, alkylarylaminocarbonyl, (di)alkylamino, haloalkylamino, haloalkylarylaminocarbonyl, (di)arylaminocarbonyl, aralkylaminocarbonyl, alkylcarbonylaminocarbonyl, haloalkylcarbonylaminocarbonyl, alkoxycarbonylaminocarbonyl, arylcarbonylaminocarbonyl, arylcarbonylaminocarbonyl, aryloxy carbonylaminocarbonyl, aryloxy carbonylaminocarbonyl, alkylenedioxyalkyl, dialkylalkylenedioxyalkyl, alkylsulfonylaminocarbonyl, alkylsulfonylaminocarbonyl, azido,

dialkylphosphonyl, alkylarylphosphonyl, diarylphosphonyl, alkylthio, arylthio, perfluoroalkylthio, hydroxycarbonylalkylthio, (iso)thiocyano, alkylsulfanyl, alkylsulfonyl, arylsulfanyl, arylsulfonyl, aminosulfonyl, alkylarninosulfonyl, dialkylarninosulfonyl, arylarninosulfonyl, diarylarninosulfonyl or alkylarylarninosulfonyl (all optionally substituted by 1-4 substituents of Q2); or

Q1Q1 = alkylendioxy, thioalkylenoxy or alkylendioxy (all substituted by 1,2 or 1,3 arrangement);

z = 1 or 2; and

Q2 = halo, pseudohalo, OH, oxo, thia, nitrile, NO2, formyl, mercapto, NH2, hydroxyalkyl, hydroxyaryl, hydroxycarbonyl, (halo)alkyl, polyhaloalkyl, (di)aminoalkyl, alkenyl containing 1-2 double bonds, alkynyl containing 1-2 triple bonds, cycloalkyl, heterocyclyl, (hetero)aryl, aralkyl, aralkenyl, aralkynyl, alkoxy, carbonyl, aryloxy, carbonyl, aralkoxy, carbonyl, arylcarbonylalkyl, aminocarbonyl, alkoxy, aryloxy, aralkoxy, alkylendioxy, NH2, (di)alkylamino, (di)arylamino, (di)alkylamino, haloalkylamino, (di)arylamino, alkylarylamino, aralkylamino, alkoxy, carbonyl, amino, arylcarbonylamino, alkylthio or arylthio.

INDEPENDENT CLAIMS are included for:

(1) a composition comprising (I);

(2) a method of reducing plasma cholesterol level or plasma triglyceride level comprising (I);

(3) a method of modulating cholesterol metabolism, catabolism, synthesis, absorption, re-absorption, secretion or excretion in a mammal comprising administering (I); and

(4) a method for modulating farnesoid X receptor activity comprising contacting a cell with (I).

ACTIVITY - Antilipemic; Hemostatic; Antiarteriosclerotic; Metabolic; Cardiovascular-Gen.; Antidiabetic; Gastrointestinal-Gen.; Anorectic.

MECHANISM OF ACTION - Farnesoid X receptor inhibitor. (I) were tested for farnesoid X receptor inhibitory activity using a biological assay. The median inhibitory concentration of 1-methylethyl 3-((3-hydroxyphenyl)carbonyl)-1,1-dimethyl-1,2,3,6-tetrahydroazepino(4,5- b)indole-5-carboxylate was 0.001-0.01 μ M.

USE - (I) are useful for the treatment, prevention, inhibition or amelioration of symptoms of a disease or disorder in which nuclear receptor activity such as hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, dyslipidemia, lipodystrophy, atherosclerosis, atherosclerotic disease, atherosclerotic disease events, atherosclerotic cardiovascular disease, Syndrome X, diabetes mellitus, type II diabetes, insulin insensitivity, hyperglycemia, cholestasis and obesity (claimed).

ADVANTAGE - (I) exhibits extremely high affinity for the farnesoid X receptor, and high potency in vivo; and has ability to reduce both plasma triglyceride and cholesterol levels in normal and hyperlipidemic animal models.

MANUAL CODE:

CPI: B01-D02; B03-D; B03-E; B03-F; B03-H; B04-C01C; B04-C01G; B04-C01H; B04-J03A; B06-B01; B06-D16; B07-D03; B07-D04B; B08-D01; B10-A23; B10-B01B; B10-B02B; B10-B03B; B10-B04B; B10-C03; B10-F02; B14-D02A2; B14-E12; B14-F01; B14-F06; B14-F06A; B14-F07; B14-F09; B14-L06; B14-S04; B14-S04A; B14-S13

L35 ANSWER 30 OF 31

ACCESSION NUMBER:

DOC. NO. NON-CPI:

TITLE:

WPIX COPYRIGHT 2008

2008-F02407 [35]

N2008-395119 [35]

THOMSON REUTERS on STN

WPIX [Full-text](#)

Gunning transceiver logic output circuit, has control end linked with dispersion gate NAND via inverters, and NAND linked with grid of drive tube negative channel metal oxide semiconductor that is coupled with assistant charge circuit

DERWENT CLASS:

T01; U11; U21

10/576653

INVENTOR: CHEN J; CHEN N; HE P; LE D; LEI J; LI S; MA J; WANG D;
WANG J; WU H; XU W; YU R; ZHANG M; ZHAO Z; ZOU J
PATENT ASSIGNEE: (UYCH-N) UNIV CHINESE PEOPLE LIBERATION ARMY NAVY
COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND DATE	WEEK	LA	PG	MAIN IPC
CN 101087138	A	20071212 (200835)*	ZH	7[5]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
CN 101087138	A	CN 2007-10035326	20070710

PRIORITY APPLN. INFO: CN 2007-10035326 20070710

INT. PATENT CLASSIF.:

IPC ORIGINAL: G06F0013-40 [I,A]; G06F0013-40 [I,C]; H03K0019-0175 [I,A]
; H03K0019-0175 [I,C]

BASIC ABSTRACT:

CN 101087138 A UPAB: 20080604

NOVELTY - The circuit has a control end linked with a dispersion gate NAND via two inverters, and an input end (IN) coupled with the NAND via one of the inverter and a third inverter. The NAND is linked with a grid of a drive tube negative channel metal oxide semiconductor (NMOS). A source electrode of the NMOS is coupled with a ground, and a drain electrode of the NMOS is linked with an output end (OUT) via a terminal resistor. The NMOS is coupled with an assistant charge circuit, and the grid of an assistant charge tube positive-channel metal oxide semiconductor (PMOS) is linked with the NMOS.

USE - Gunning transceiver logic (GTL) output circuit.

ADVANTAGE - The structure of the structure is simple, and the circuit quickly charges the board electrode loading and satisfies the demand of the high frequency. The circuit has better characteristic of anti-change of technique, voltage and temperature.

DESCRIPTION OF DRAWINGS - The drawing shows a circuit diagram of a gunning transceiver logic circuit.'(Drawing includes non-English language text)'.
Input end (IN)
Output end (OUT)

MANUAL CODE: EPI: T01-H07A; U11-C05E; U21-C02

L35 ANSWER 31 OF 31 WPIX COPYRIGHT 2008 THOMSON REUTERS on STN
ACCESSION NUMBER: 2008-D27778 [25] WPIX Full-text
DOC. NO. NON-CPI: N2008-257019 [25]
TITLE: Radio-frequency identification reader
T01; T04; W02
DERIVENT CLASS:
INVENTOR: CHENG W; DU X; HUANG J; LIU W; XU J; XU W; YU J; ZHAO M
PATENT ASSIGNEE: (UYHU-N) UNIV HUAZHONG SINCE & TECHNOLOGY
COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND DATE	WEEK	LA	PG	MAIN IPC
CN 101013463	A	20070808 (200825)*	ZH	[1]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
CN 101013463 A		CN 2006-10125133	20061124

PRIORITY APPLN. INFO: CN 2006-10125133 20061124
 INT. PATENT CLASSIF.:
 IPC ORIGINAL: G06K0007-00 [I,A]; G06K0007-00 [I,C]
 BASIC ABSTRACT:
 CN 101013463 A UPAB: 20080417
 NOVELTY - Radio-frequency identification reader belongs to the data read-write handling processor which solves problems such as signal frequency and low intelligentizing of existing reader. In invention comprises micro processor, memorizer, programmable logic device, I/O interface, digital signals processor, radio-frequency artificial circuit, wireless communication module, display screen. The radio-frequency artificial circuit comprises N radio-frequency artificial circuits with different frequencies. N is no less than 2 and is natural number; this invention has integrated radio-frequency identification technology, software wireless communication technology, wireless communication technology and intelligentizing information processing. It can not only achieve identification of all kinds of E-tags but also achieve localizing information processing. Data long-distance alternation is achieved through wireless or line communication at the same time. MANUAL CODE: EPI: T01-C07C3; T01-E01; T01-M05; T04-K02B; T04-K02C; T04-K03B; W02-G05

=> file registry

FILE 'REGISTRY' ENTERED AT 15:51:12 ON 01 OCT 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 30 SEP 2008 HIGHEST RN 1055704-91-0
 DICTIONARY FILE UPDATES: 30 SEP 2008 HIGHEST RN 1055704-91-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

Uploading L5.str



0 = 1
 5 = 2
 N = 3
 C = 4

9 = 1
 16 = 2
 11 = 3
 12 = 4

chain nodes :
 7 8 22

10/576653

```
ring nodes :  
1 2 3 4 5 6 25 26 27 28 29 30  
ring/chain nodes :  
9 10 11 12 18 19 21 24  
chain bonds :  
2-7 5-8 21-22  
ring/chain bonds :  
6-18 18-19 19-21 21-24 24-27  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 25-26 25-30 26-27 27-28 28-29 29-30  
exact/norm bonds :  
1-2 1-6 2-3 2-7 3-4 4-5 5-6 5-8 6-18 18-19 19-21 21-22 21-24 24-27  
25-26 25-30 26-27 27-28 28-29 29-30
```

G2:[*1],[*2],[*3],[*4]

G3:C,N

Connectivity :

7:1 E exact RC ring/chain 21:3 E exact RC ring/chain 22:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 18:CLASS 19:CLASS 21:CLASS 22:CLASS 24:CLASS 25:Atom
26:Atom 27:Atom
28:Atom 29:Atom 30:Atom

=> file zcaplus

FILE 'ZCAPLUS' ENTERED AT 15:51:15 ON 01 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 1 Oct 2008 VOL 149 ISS 14

FILE LAST UPDATED: 30 Sep 2008 (20080930/ED)

ZCaplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'ZCAPLUS' FILE

10/576653

=> d stat que L8
L5 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L7 156 SEA FILE=REGISTRY SSS FUL L5
L8 2 SEA FILE=ZCAPLUS ABB=ON PLU=ON L7

=> file beilstein

FILE 'BEILSTEIN' ENTERED AT 15:51:24 ON 01 OCT 2008

COPYRIGHT (c) 2008 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE LAST UPDATED ON April 1, 2008

FILE COVERS 1771 TO 2008.

*** FILE CONTAINS 10.322,808 SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in
separate documents and can not be searched together in one query.
Reaction data for BEILSTEIN compounds may be displayed
immediately with the display codes PRE (preparations) and REA
(reactions). A substance answer set retrieved after the search
for a chemical name, a compounds with available reaction
information by combining with PRE/FA, REA/FA or more generally
with RX/FA. The BEILSTEIN Registry Number (BRN) is the link
between a BEILSTEIN compound and belonging reactions. For mo
detailed reaction searches BRNs can be searched as reaction
partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *

>>> Price change as of January 1st, 2008: Connect Time and Structure
Search fees re-introduced. See NEWS and HELP COST <<<

=> d stat que L10
L5 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L10 0 SEA FILE=BEILSTEIN SSS FUL L5

100.0% PROCESSED 776 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.10

=> file wpix

FILE 'WPIX' ENTERED AT 15:51:33 ON 01 OCT 2008

10/576653

COPYRIGHT (C) 2008 THOMSON REUTERS

FILE LAST UPDATED: 30 SEP 2008 <20080930/UP>
MOST RECENT UPDATE: 200862 <200862/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.1 million chemical structures in DCR <<<

>>> IPC Reform backfile reclassifications have been loaded to the end of June 2008. No update date (UP) has been created for the reclassified documents, but they can be identified by 20060101/UPIC and 20061231/UPIC, 20070601/UPIC, 20071001/UPIC, 20071130/UPIC, 20080401/UPIC and 20080701/UPIC. ECLA reclassifications to June and US national classifications to the end of April 2008 have also been loaded. Update dates 20080401 and 20080701/UPEC and /UPNC have been assigned to these. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://scientific.thomsonreuters.com/support/patents/coverage/latestupdates/>

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:
http://www.stn-international.com/archive/presentations/DWFIAnaVist2_0608.pdf

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

'BIX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> d stat que L13
L5 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L12 49 SEA FILE=WPIX SSS FUL L5
L13 1 SEA FILE=WPIX ABB=ON PLU=ON L12/DCR

=> file marpat
FILE 'MARPAT' ENTERED AT 15:51:40 ON 01 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 149 ISS 12 (20080926/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 20080194825 14 AUG 2008
DE 102007007185 14 AUG 2008
EP 1956050 13 AUG 2008
JP 2008182009 07 AUG 2008
WO 2008102086 28 AUG 2008
GB 2444641 11 JUN 2008


10/576653

FR 2912404 15 AUG 2008
RU 2330029 27 JUL 2008
CA 2615024 14 JUN 2008

Expanded G-group definition display now available.

Effective December 15th the iteration and answer limits in MARPAT have increased from 100,000 to 200,000 for both on-line and batch searches. For more information on MARPAT search limits, type HELP SLIMITS at an arrow prompt.

Uploading L14.str



0 * 1
s * 2
N * 3
c * 4

9 * 1
16 * 2
11 * 3
12 * 4

```
chain nodes :
7 8 22
ring nodes :
1 2 3 4 5 6 25 26 27 28 29 30
ring/chain nodes :
9 10 11 12 18 19 21 24
chain bonds :
2-7 5-8 6-18 18-19 19-21 21-22 21-24 24-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 25-26 25-30 26-27 27-28 28-29 29-30
exact/norm bonds :
1-2 1-6 2-3 2-7 3-4 4-5 5-6 5-8 6-18 18-19 19-21 21-22 21-24 24-27
25-26 25-30 26-27 27-28 28-29 29-30
```

G2:[*1],[*2],[*3],[*4]

G3:C,N

10/576653

Connectivity :

7:1 E exact RC ring/chain 21:3 E exact RC ring/chain 22:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 18:CLASS 19:CLASS 21:Atom 22:Atom 24:Atom 25:Atom 26:Atom
27:Atom 28:Atom
29:Atom 30:Atom

=> d stat que L17

L14 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L16 15 SEA FILE=MARPAT SSS FUL L14

L17 13 SEA FILE=MARPAT ABB=ON PLU=ON L16/COM

=> dup rem L8 L10 L13 L17

L10 HAS NO ANSWERS

DUPLICATE IS NOT AVAILABLE IN 'BEILSTEIN'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

FILE 'ZCAPLUS' ENTERED AT 15:52:01 ON 01 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 15:52:01 ON 01 OCT 2008

COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'MARPAT' ENTERED AT 15:52:01 ON 01 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

PROCESSING COMPLETED FOR L8

PROCESSING COMPLETED FOR L10

PROCESSING COMPLETED FOR L13

PROCESSING COMPLETED FOR L17

L36 15 DUP REM L8 L10 L13 L17 (1 DUPLICATE REMOVED)

ANSWERS '1-2' FROM FILE ZCAPLUS

ANSWERS '3-15' FROM FILE MARPAT

=> d ibib abs hitstr L36 1-2; d ibib abs qhit L36 3-15

L36 ANSWER 1 OF 15 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2005:395042 ZCAPLUS Full-text

DOCUMENT NUMBER: 142:447414

TITLE: P70S6 kinase modulators and method of use

INVENTOR(S): Cheng, Wei; Co, Erick Wang; Kim, Moon Hwan; Klein,
Rhett Ronald; Le Donna, T.; Lew, Amy; Nuss, John M.;
Xu, Wei

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 165 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

10/576653

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039506	A2	20050506	WO 2004-US35470	20041022
WO 2005039506	A3	20060119		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004283751	A1	20050506	AU 2004-283751	20041022
CA 2541989	A1	20050506	CA 2004-2541989	20041022
EP 1678168	A2	20060712	EP 2004-796443	20041022
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007527413	T	20070927	JP 2006-536929	20041022
US 20070208020	A1	20070906	US 2006-576653	20061116
PRIORITY APPLN. INFO.:			US 2003-514432P	P 20031024
			US 2004-551429P	P 20040308
			WO 2004-US35470	W 20041022

OTHER SOURCE(S): CASREACT 142:447414; MARPAT 142:447414
 GI



AB Peptide derivs. I [E = C(R2)-substituted pyridine, pyridazine, pyrimidine, or 1,3,5-triazine; B = (R1)n; R1, R2 = H, halo, trihalomethyl, CN, NO2, aminoalkyl, carboxyalkyl, (un)substituted alky, alkenyl, alkynyl, aryl, heterocyclyl, heterocyclyl, heterocyclylalkyl, arylalkyl, etc.; X, Y = CO, O, (un)substituted amine, (un)substituted imine, SO; X and Y can combine to form either C(R3):C(R3), or C.tplbond.C; when X = O, (un)substituted amine, or (un)substituted imine, Y cannot be CH(R3); R3 = (un)substituted Ph, naphthyl, cyclohexyl, dihydronaphthyl, five- to six-membered heteroaryl; Z = O, S, double bond to an atom of B; A = single bond, NH, (un)substituted aminoalkyl,

aminoaryl, aminoaryllalkyl, aminoheterocyclyl, aminoheterocyclylalkyl; J = (un)substituted five- to ten-membered aryl or heteroaryl, etc.; n = 0-5] or pharmaceutically acceptable salts, hydrates, or prodrugs were prepared as p70S6 kinase signal transduction inhibitors and cellular activities modulators for treating kinase-dependent diseases and conditions. Thus, compound II was prepared by coupling of 2-amino-4,6-di-chloro-5-formylpyrimidine with 2-amino-N-(3- trifluoromethylphenyl)acetamide in 43%yield and showed IC50 < 50 nM in p70S6 kinase activity assey.

IT 339156-77-3P 851333-72-7P 851333-76-1P


851334-00-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of peptidomimetics as p70S6 kinase inhibitors and cellular activities modulators for treating kinase-dependent diseases)

RN 339156-77-3 ZCAPLUS


CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]thio]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851333-72-7 ZCAPLUS


CN Propanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851333-76-1 ZCAPLUS

CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]thio]-N-[2-amino-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851334-00-4 ZCAPLUS
 CN Propanamide, 2-[[2-amino-5-cyano-6-(methylsulfinyl)-4-pyrimidinyl]amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 328285-74-1P 339582-02-4P 354553-01-8P
 851332-56-4P 851332-65-5P 851332-76-8P
 851332-85-9P 851332-91-7P 851333-03-4P
 851333-17-0P 851333-22-7P 851333-24-9P
 851333-26-1P 851333-28-3P 851333-38-5P
 851333-60-3P 851333-61-4P 851333-62-5P
 851333-74-9P 851333-80-7P 851333-84-1P
 851333-86-3P 851333-88-5P 851333-90-9P
 851333-92-1P 851333-96-5P 851333-98-7P
 851334-02-6P 851334-06-0P 851334-08-2P
 851334-10-6P 851334-12-8P 851334-14-0P
 851334-16-2P 851334-18-4P 851334-20-8P
 851334-22-0P 851334-24-2P 851334-26-4P
 851334-28-6P 851334-29-7P 851334-30-0P
 851334-31-1P 851334-33-3P 851334-34-4P
 851334-35-5P 851334-36-6P 851334-37-7P
 851334-40-2P 851334-42-4P 851334-44-6P
 851334-45-7P 851334-47-9P 851334-48-0P
 851334-50-4P 851334-51-5P 851334-52-6P
 851334-53-7P 851334-54-8P 851334-55-9P
 851334-56-0P 851334-58-2P 851334-61-7P
 851334-62-8P 851334-63-9P 851334-64-0P
 851334-66-2P 851334-68-4P 851334-70-8P
 851334-72-0P 851334-74-2P 851334-76-4P
 851334-78-6P 851334-80-0P 851334-81-1P
 851334-82-2P 851334-83-3P 851334-84-4P
 851334-85-5P 851334-87-7P 851334-89-9P
 851334-90-2P 851334-91-3P 851334-93-5P
 851334-95-7P 851334-97-9P 851334-99-1P
 851335-00-7P 851335-02-9P 851335-04-1P
 851335-05-2P 851335-06-3P 851335-08-5P
 851335-11-0P 851335-13-2P 851335-15-4P
 851335-17-6P 851335-19-8P 851335-21-2P
 851335-24-5P 851335-26-7P 851335-27-8P
 851335-28-9P 851335-29-0P 851335-30-3P
 851335-31-4P 851335-34-7P 851335-35-8P
 851335-37-0P 851335-39-2P 851335-41-6P


851335-43-8P 851335-45-0P 851335-46-1P
 851335-47-2P 851335-48-3P 851335-49-4P
 851335-50-7P 851335-51-8P 851335-53-0P
 851335-55-2P 851335-56-3P 851335-57-4P
 851335-59-6P 851335-60-9P 851335-62-1P
 851335-64-3P 851335-65-4P 851335-66-5P
 851335-67-6P 851335-68-7P 851335-70-1P
 851335-71-2P 851335-72-3P 851335-73-4P
 851335-75-6P 851335-77-8P 851335-78-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of peptidomimetics as p70S6 kinase inhibitors and cellular
 activities modulators for treating kinase-dependent diseases)


RN 328285-74-1 ZCAPLUS

CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]thio]-N-(4-
 chlorophenyl)- (CA INDEX NAME)




RN 339582-02-4 ZCAPLUS

CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]thio]-N-(3-
 butoxyphenyl)- (CA INDEX NAME)



RN 354553-01-8 ZCAPLUS


CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]thio]-N-2-
 pyridinyl- (CA INDEX NAME)



RN 851332-56-4 ZCAPLUS


CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]thio]-N-[5-
 (trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)

10/576653




RN 851332-65-5 ZCAPLUS

CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]thio]-N-(3-methoxyphenyl)- (CA INDEX NAME)




RN 851332-76-8 ZCAPLUS

CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]thio]-N-(3-chlorophenyl)- (CA INDEX NAME)




RN 851332-85-9 ZCAPLUS

CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]oxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851332-91-7 ZCAPLUS

CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]thio]-N-methyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851333-03-4 ZCAPLUS

CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851333-17-0 ZCAPLUS

CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]thio]-N-[4-fluoro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851333-22-7 ZCAPLUS


CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]thio]-N-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851333-24-9 ZCAPLUS


CN 5-Pyrimidinecarbonitrile, 2-amino-4-(methylthio)-6-[[2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyrrolidinyl]thio]- (CA INDEX NAME)

10/576653




RN 851333-26-1 ZCAPLUS

CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]thio]-N-[6-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 851333-28-3 ZCAPLUS


CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]thio]-N-[4-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 851333-38-5 ZCAPLUS


CN Propanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]oxy]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851333-60-3 ZCAPLUS

CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]thio]-N-[2-methyl-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851333-61-4 ZCAPLUS

CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]thio]-N-[2-methoxy-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851333-62-5 ZCAPLUS

CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]thio]-N-[2-chloro-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851333-74-9 ZCAPLUS

CN Acetamide, 2-[[2-amino-5-cyano-6-(methylamino)-4-pyrimidinyl]thio]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851333-80-7 ZCAPLUS

CN Hydrazinecarboxamide, 2-[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]-N-


10/576653

[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851333-84-1 ZCAPLUS


CN Acetamide, 2-[[2-amino-5-cyano-6-(dimethylamino)-4-pyrimidinyl]thio]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851333-86-3 ZCAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851333-88-5 ZCAPLUS


CN Propanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]oxy]-N-[3-(trifluoromethyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 851333-90-9 ZCAPLUS


CN Cyclopropanecarboxamide, 1-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]oxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851333-92-1 ZCAPLUS


CN Butanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]oxy]-3-methyl-N-[3-(trifluoromethyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 851333-96-5 ZCAPLUS


CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]methylamino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851333-98-7 ZCAPLUS

CN Cyclopropanecarboxamide, 1-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)


10/576653



RN 851334-02-6 ZCAPLUS


CN Propanamide, 2-[(2-amino-5-cyano-6-(methylsulfonyl)-4-pyrimidinyl)amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 851334-06-0 ZCAPLUS


CN Acetamide, 2-[(2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl)thio]-N-[3,5-bis(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851334-08-2 ZCAPLUS

CN Propanamide, 2-[(2-amino-5-cyano-6-methoxy-4-pyrimidinyl)amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-10-6 ZCAPLUS

CN Propanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-N-[2-methoxy-5-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-12-8 ZCAPLUS

CN Propanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-N-[2-chloro-5-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-14-0 ZCAPLUS

CN Propanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-N-methyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)


10/576653



RN 851334-16-2 ZCAPLUS

CN Propanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-N-[3-[(4-methyl-1-piperazinyl)carbonyl]phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-18-4 ZCAPLUS


CN Propanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-N-[3-(trifluoromethyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 851334-20-8 ZCAPLUS

CN Acetamide, 2-[[2-amino-5-cyano-6-(4-morpholinyl)-4-pyrimidinyl]thio]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




10/576653

RN 851334-22-0 ZCAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]-N-[3-(trifluoromethyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-24-2 ZCAPLUS


CN Pentanamide, 5-amino-2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 851334-26-4 ZCAPLUS

CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl][2-(dimethylamino)ethyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851334-28-6 ZCAPLUS

CN Propanamide, 2-[[2-amino-5-cyano-6-ethoxy-4-pyrimidinyl]amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


10/576653



RN 851334-29-7 ZCAPLUS

CN Propanamide, 2-[(2,6-diamino-5-cyano-4-pyrimidinyl)amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-30-0 ZCAPLUS

CN Propanamide, 2-[(2-amino-5-cyano-4-pyrimidinyl)amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851334-31-1 ZCAPLUS

CN Propanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]methylamino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


10/576653



RN 851334-33-3 ZCAPLUS


CN Propanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-N-[3-[2-(diethylamino)ethoxy]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 851334-34-4 ZCAPLUS

CN Hydrazinecarboxamide, 2-[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]-1,2-dimethyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851334-35-5 ZCAPLUS

CN Propanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-N-[3-amino-5-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.

10/576653




RN 851334-36-6 ZCAPLUS

CN Acetic acid, 2-[1-[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]-2-[[3-(trifluoromethyl)phenyl]amino]carbonylhydrazinyl]-, ethyl ester (CA INDEX NAME)



RN 851334-37-7 ZCAPLUS

CN Hydrazinecarboxamide, 2-[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]-2-methyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851334-40-2 ZCAPLUS

CN Propanamide, 2-[(2-amino-5-cyano-1,6-dihydro-6-oxo-4-pyrimidinyl)amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.

10/576653



RN 851334-42-4 ZCAPLUS


CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl][(tetrahydro-2H-pyran-4-yl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851334-44-6 ZCAPLUS

CN Propanamide, 2-[[2-amino-5-cyano-6-[2-(dimethylamino)ethoxy]-4-pyrimidinyl]amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851334-45-7 ZCAPLUS

CN Carbamic acid, [(5S)-5-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-6-oxo-6-[[3-(trifluoromethyl)phenyl]amino]hexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/576653



RN 851334-47-9 ZCAPLUS


CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl][2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851334-48-0 ZCAPLUS

CN Propanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-N-[[2-(diethylamino)ethyl]amino]-5-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-50-4 ZCAPLUS


CN Propanamide, 2,2'-[[2-amino-5-cyano-4,6-pyrimidinediyl]diimino]bis[N-[3-(trifluoromethyl)phenyl]-, (2S,2'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851334-51-5 ZCAPLUS

CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]methylamino]-N-(3-methylphenyl)- (CA INDEX NAME)



RN 851334-52-6 ZCAPLUS


CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]methylamino]-N-[3-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 851334-53-7 ZCAPLUS

CN Pentanamide, 2-[[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-5-[[imino(nitroamino)methyl]amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




10/576653

RN 851334-54-8 ZCAPLUS

CN Benzoic acid, 3-[[[2S]-2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-1-oxopropyl]amino]-5-(trifluoromethyl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-55-9 ZCAPLUS

CN Propanamide, 2-[[[2S]-2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-N-(3-nitrophenyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-56-0 ZCAPLUS

CN Hexanamide, 6-amino-2-[[[2S]-2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-N-(3-(trifluoromethyl)phenyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-58-2 ZCAPLUS

CN Propanamide, 2-[(2-amino-5-cyano-6-propoxy-4-pyrimidinyl)amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-61-7 ZCAPLUS

CN Pentanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-5-[(aminoiminomethyl)amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-62-8 ZCAPLUS

CN Propanamide, 2-[[2-amino-5-cyano-6-(methylsulfinyl)-4-pyrimidinyl]methylamino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-63-9 ZCAPLUS

CN Propanamide, 2-[(2-amino-5-cyano-6-methoxy-4-pyrimidinyl)methylamino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-64-0 ZCAPLUS

CN Propanamide, 2-[(2-amino-5-cyano-6-propoxy-4-pyrimidinyl)methylamino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-66-2 ZCAPLUS

CN Propanamide, 2-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)methylamino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-68-4 ZCAPLUS

CN Propanamide, 2-[[2-amino-5-cyano-6-(1-methylethoxy)-4-pyrimidinyl]amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-70-8 ZCAPLUS

CN Pentanamide, 5-(acetlamino)-2-[[2-amino-5-cyano-6-(methythio)-4-pyrimidinyl]amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-72-0 ZCAPLUS

CN Propanamide, 2-[[2-amino-5-cyano-6-(methythio)-4-pyrimidinyl]amino]-N-(3-aminophenyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-74-2 ZCAPLUS

CN Benzamide, 3-[(2S)-2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-1-oxopropyl]amino]-N-[2-(dimethylamino)ethyl]-5-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-76-4 ZCAPLUS

CN Carbamic acid, [(4S)-4-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-5-oxo-5-[[3-(trifluoromethyl)phenyl]amino]pentyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851334-78-6 ZCAPLUS

CN Hydrazinecarboxamide, 2-(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

10/576653


(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851334-80-0 ZCAPLUS

CN Carbamic acid, [(4S)-4-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-5-oxo-5-[[3-(trifluoromethyl)phenyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-81-1 ZCAPLUS

CN Pentanamide, 5-amino-2-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-82-2 ZCAPLUS

CN Benzamide, 3-[[[(2S)-2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]methylamino]-1-oxopropyl]amino]-N-[2-(dimethylamino)ethyl]-5-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-83-3 ZCAPLUS

CN Benamide, 3-[[2S]-2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]methylamino]-1-oxopropyl]amino]-N-[3-(4-methyl-1-piperazinyl)propyl]-5-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-84-4 ZCAPLUS

CN Propanamide, 2-[[2S]-2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]methylamino]-N-[3-(trifluoromethoxy)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851334-85-5 ZCAPLUS

CN Propanamide, 2-[[2S]-2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]methylamino]-N-(3-bromophenyl)-, (2S)- (CA INDEX NAME)

10/576653


Absolute stereochemistry.



RN 851334-87-7 ZCAPLUS

CN Propanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]methylamino]-N-[2-[2-(dimethylamino)ethoxy]-5-(trifluoromethoxy)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-89-9 ZCAPLUS

CN Benzamide, 3-[[[(2S)-2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]methylamino]-1-oxopropyl]amino]-N-[2-(4-morpholinyl)ethyl]-5-(trifluoromethoxy)- (CA INDEX NAME)

Absolute stereochemistry.




10/576653

RN 851334-90-2 ZCAPLUS

CN Hexanamide, 6-amino-2-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)methylamino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851334-91-3 ZCAPLUS

CN Propanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-N-[3-[2-(dimethylamino)ethoxy]-5-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851334-93-5 ZCAPLUS

CN Propanamide, 3-(acetyloxy)-2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


10/576653



RN 851334-95-7 ZCAPLUS


CN Pentanediamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 851334-97-9 ZCAPLUS

CN Hydrazinecarboxamide, 2-(2-amino-5-cyano-6-methoxy-4-pyrimidinyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851334-99-1 ZCAPLUS

CN Benzamide, 3-[[[(2S)-2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-1-oxopropyl]amino]-N-hydroxy-5-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.


10/576653



RN 851335-00-7 ZCAPLUS

CN Propanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-3-(dimethylamino)-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-02-9 ZCAPLUS

CN 4-Morpholinepentanamide, α-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-N-[3-(trifluoromethyl)phenyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851335-04-1 ZCAPLUS

CN Pentanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-5-[(2-methoxyethyl)amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


10/576653



RN 851335-05-2 ZCAPLUS

CN Benzoic acid, 3-[[2S]-2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-1-oxopropyl]amino]-5-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-06-3 ZCAPLUS

CN Pentanoic acid, 4-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-5-oxo-5-[[3-(trifluoromethyl)phenyl]amino]-, methyl ester, (4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851335-08-5 ZCAPLUS

CN Pentanamide, 5-[[aminocarbonyl]amino]-2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

10/576653


Absolute stereochemistry.



RN 851335-11-0 ZCAPLUS

CN Pentanoic acid, 4-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-5-oxo-5-[3-(trifluoromethyl)phenyl]amino]-, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-13-2 ZCAPLUS

CN Propanamide, 2-[[2-amino-5-cyano-6-ethoxy-4-pyrimidinyl]amino]-3-hydroxy-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851335-15-4 ZCAPLUS

CN Propanamide, 2-[[2-amino-5-cyano-6-ethoxy-4-pyrimidinyl]amino]-3-(phenylmethoxy)-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

10/576653


Absolute stereochemistry.



RN 851335-17-6 ZCAPLUS

CN Pentanamide, 2-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-5-[(aminoiminomethyl)amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-19-8 ZCAPLUS

CN Carbamic acid, [(5S)-5-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]methylamino]-6-oxo-6-[[3-(trifluoromethyl)phenyl]amino]hexyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851335-21-2 ZCAPLUS

CN Benzenepropanamide, α-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-4-hydroxy-N-[3-(trifluoromethyl)phenyl]-, (αS)-

10/576653

(CA INDEX NAME)


Absolute stereochemistry.



RN 851335-24-5 ZCAPLUS

CN Hexanamide, 2-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-6-(dimethylamino)-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-26-7 ZCAPLUS

CN Propanamide, 2-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-N-[3-[(4-methyl-1-piperazinyl)carbonyl]-5-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851335-27-8 ZCAPLUS

CN Benzamide, 3-[(2S)-2-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-1-oxopropyl]amino-N-[3-(1-pyrrolidinyl)propyl]-5-(trifluoromethyl)- (CA

10/576653

INDEX NAME)


Absolute stereochemistry.



RN 851335-28-9 ZCAPLUS

CN Benzamide, 3-[[[(2S)-2-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-1-oxopropyl]amino]-N-[2-(4-morpholinyl)ethyl]-5-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-29-0 ZCAPLUS

CN Benzamide, 3-[[[(2S)-2-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-1-oxopropyl]amino]-N-[2-(dimethylamino)ethyl]-5-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-30-3 ZCAPLUS

CN Benzamide, 3-[[(2S)-2-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-1-oxopropyl]amino]-N-[3-(4-methyl-1-piperazinyl)propyl]-5-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-31-4 ZCAPLUS

CN Carbamic acid, [(5S)-5-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)methylamino]-6-oxo-6-[[3-(trifluoromethyl)phenyl]amino]hexyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851335-34-7 ZCAPLUS

CN Propanamide, 3-(acetyloxy)-2-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

10/576653


Absolute stereochemistry.



RN 851335-35-8 ZCAPLUS

CN Pentanoic acid, 4-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-5-oxo-5-[[3-(trifluoromethyl)phenyl]amino]-, phenylmethyl ester, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-37-0 ZCAPLUS

CN 4-Morpholinepentanamide, α -[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-N-[3-(trifluoromethyl)phenyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851335-39-2 ZCAPLUS

CN 1-Pentaminium, 4-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-N,N,N-

10/576653

trimethyl-5-oxo-5-[[3-(trifluoromethyl)phenyl]amino]-, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-41-6 ZCAPLUS

CN Pentanoic acid, 4-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-5-oxo-5-[[3-(trifluoromethyl)phenyl]amino]-, methyl ester, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-43-8 ZCAPLUS

CN Hexanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-6-(dimethylamino)-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851335-45-0 ZCAPLUS

CN Propanamide, 2-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)methylamino]-N-[3-

10/576653

| (trifluoromethoxy)phenyl]-, (2S)- | (CA INDEX NAME) |


Absolute stereochemistry.



RN 851335-46-1 ZCAPLUS

CN Pentanoic acid, 4-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-5-oxo-5-
[[3-(trifluoromethyl)phenyl]amino]-, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-47-2 ZCAPLUS

CN Propanamide, 2-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)methylamino]-N-(3-bromophenyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851335-48-3 ZCAPLUS

CN Pentanediamide, 2-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-N1-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

10/576653


Absolute stereochemistry.



RN 851335-49-4 ZCAPLUS

CN Propanamide, 2-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-3-(dimethylamino)-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-50-7 ZCAPLUS

CN Pentanoic acid, 4-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-5-oxo-5-[[3-(trifluoromethyl)phenyl]amino]-, hydrazide, (4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851335-51-8 ZCAPLUS

CN Propanamide, 2-[(2-amino-5-cyano-6-methoxy-4-pyrimidinyl)amino]-3-(dimethylamino)-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

10/576653


Absolute stereochemistry.



RN 851335-53-0 ZCAPLUS

CN Propanamide, 2-[(2-amino-5-cyano-6-methoxy-4-pyrimidinyl)amino]-N-[3-[2-(dimethylamino)ethoxy]-5-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-55-2 ZCAPLUS

CN Propanamide, 2-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-N-[3-[2-(dimethylamino)ethoxy]-5-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851335-56-3 ZCAPLUS

CN Propanamide, 2-[(2-amino-5-cyano-6-methoxy-4-pyrimidinyl)methylamino]-N-(3-bromophenyl)-, (2S)- (CA INDEX NAME)

10/576653


Absolute stereochemistry.



RN 851335-57-4 ZCAPLUS

CN Pentanoic acid, 4-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-5-oxo-5-[[3-(trifluoromethyl)phenyl]amino]-, phenylmethyl ester, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-59-6 ZCAPLUS

CN Propanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-3-oxo-N-[[3-(trifluoromethyl)phenyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851335-60-9 ZCAPLUS

CN Pentanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-5-oxo-N-bis(2-methoxyethyl)amino-N-[[3-(trifluoromethyl)phenyl]amino]-, (2S)- (CA INDEX NAME)

10/576653

INDEX NAME)


Absolute stereochemistry.



RN 851335-62-1 ZCAPLUS

CN Carbamic acid, [(4S)-4-[(2-amino-5-cyano-6-methoxy-4-pyrimidinyl)amino]-5-oxo-5-[3-(trifluoromethyl)phenyl]aminopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-64-3 ZCAPLUS

CN Pentanamide, 5-(acetlamino)-2-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851335-65-4 ZCAPLUS

CN Propanamide, 2-[(2-amino-5-cyano-6-methoxy-4-pyrimidinyl)methylamino]-N-[3-

10/576653

(trifluoromethoxy)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-66-5 ZCAPLUS

CN Benzoic acid, 3-[[(2S)-2-[(2-amino-5-cyano-6-methoxy-4-pyrimidinyl)amino]-1-oxopropyl]amino]-5-(trifluoromethyl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-67-6 ZCAPLUS

CN Benzamide, 3-[[(2S)-2-[(2-amino-5-cyano-6-methoxy-4-pyrimidinyl)amino]-1-oxopropyl]amino]-N-[2-(dimethylamino)ethyl]-5-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




10/576653

RN 851335-68-7 ZCAPLUS

CN 4-Morpholinepropanamide, α -[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-N-[3-(trifluoromethyl)phenyl]-, (α S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-70-1 ZCAPLUS

CN 4-Morpholinepropanamide, α -[(2-amino-5-cyano-6-methoxy-4-pyrimidinyl)amino]-N-[3-(trifluoromethyl)phenyl]-, (α S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851335-71-2 ZCAPLUS

CN 4-Morpholinepropanamide, α -[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-N-[3-(trifluoromethyl)phenyl]-, (α S)- (CA INDEX NAME)

Absolute stereochemistry.


10/576653



RN 851335-72-3 ZCAPLUS

CN Pentanamide, 5-[(aminocarbonyl)amino]-2-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-73-4 ZCAPLUS

CN Hexanamide, 6-amino-2-[(2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl)amino]-N-[3-(trifluoromethyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-75-6 ZCAPLUS

CN Hexanamide, 6-amino-2-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-N-[3-(trifluoromethyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-77-8 ZCAPLUS

CN Propanamide, 2-[(2-amino-5-cyano-6-ethoxy-4-pyrimidinyl)amino]-3-methoxy-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851335-78-9 ZCAPLUS

CN Pentanamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]amino]-5-[(methylsulfonyl)amino]-N-[3-(trifluoromethyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 851335-79-0P 851336-21-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of peptidomimetics as p70S6 kinase inhibitors and cellular activities modulators for treating kinase-dependent diseases)

RN 851335-79-0 ZCAPLUS


10/576653

CN Acetamide, 2-[[2-amino-5-cyano-6-(methylsulfinyl)-4-pyrimidinyl]thio]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 951336-21-5 ZCAPLUS

CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]thio]-N-[2-amino-4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



L36 ANSWER 2 OF 15 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:61837 ZCAPLUS [Full-text](#)

DOCUMENT NUMBER: 146:156236

TITLE: Cellular cholesterol absorption modifiers, and their therapeutic use

INVENTOR(S): Gardiner, Elisabeth M.; Duron, Sergio G.; Massari, Mark E.; Severance, Daniel L.; Semple, Joseph E.

PATENT ASSIGNEE(S): Kalypsys, Inc., USA

SOURCE: PCT Int. Appl., 300pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007008541	A2	20070118	WO 2006-US26242	20060705
WO 2007008541	A3	20070726		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,			

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 PRIORITY APPLN. INFO.: US 2005-697659P P 20050708
 US 2005-697686P P 20050708
 US 2005-697814P P 20050708
 US 2005-727646P P 20051017
 US 2006-782303P P 20060313


OTHER SOURCE(S): MARPAT 146:156236

AB The invention discloses compds. and methods useful as inhibitors of cholesterol absorption for the treatment or prevention of vascular disease and atherosclerosis.

IT 328281-97-6
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cholesterol absorption modifiers and therapeutic use)

RN 328281-97-6 ZCAPLUS

CN Acetamide, 2-[[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]thio]-N-(4-methylphenyl)- (CA INDEX NAME)



L36 ANSWER 3 OF 15 MARPAT COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 148:561895 MARPAT Full-text

TITLE: Multi-cyclic compounds as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases

INVENTOR(S): Hodous, Brian L.; Geuns-Meyer, Stephanie D.; Olivieri, Philip R.; Patel, Vinod F.; Tempest, Paul

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: PCT Int. Appl., 71pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008057280	A1	20080515	WO 2007-US22712	20071025
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,			

GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:


US 2006-863172P 20061027

GI



AB The invention relates to compds. of formula I, synthetic intermediates, and pharmaceutical compns., comprising such compds. The compds. and compns. are capable of modulating various protein kinase receptors such as Tie-2 and Aurora and, therefore, influencing kinase related disease states and conditions. The compds., for example, are capable of treating cancer caused by unregulated angiogenesis, and inflammation as well as other proliferative disorders. Compds. of formula I wherein B¹, B², B³, B⁴, C¹ and C² are independently CR³ and N, provided that no more than two of B¹, B², B³ and B⁴ is N; D is 5-membered heteroaryl; L¹ is NR³, O, S, CO, SO, SO₂ and CR³R³; L² is CO, SO₂, NR³, (CR³R³)_nCONR³, CO₂, etc.; R¹ is H, (un)substituted C¹-10 alkyl, (un)substituted C²-10 alkenyl, (un)substituted C²-10 alkynyl, (un)substituted C³-7 cycloalkyl; R² and each R³ are independently H, C¹-10 alkyl, halo, CN, haloalkyl, NO₂, NH₂, etc.; R⁴ is (un)substituted C¹-10 alkyl, (un)substituted C²-10 alkenyl and (un)substituted C²-10 alkyl, etc.; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their protein kinase inhibitory activity.

MSTR 1



G1 = 43-3 47-5



G2 = CN / NH2
G10 = 134 / 148

134-137 138-139

G12 = NH
G13 = G14
G14 = (1-2) CH2 (opt. substd.)
G17 = G29
G18 = 154-4 156-149

134-C(=O)-132

G19 = G29
G29 = Ph

Patent location:

claim 1

Note: or pharmaceutically acceptable salts

substitution is restricted

Note: additional substitution also claimed

Note: also incorporates claim 9

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 4 OF 15 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 149:45205 MARPAT Full-text

TITLE: Isoindoles and derivatives, aryl and heterocyclic compounds as inhibitors of vascular endothelial growth factor receptors, and use in the treatment of cancer

INVENTOR(S): Rathinavelu, Appu; Dakshanamurthy, Sivanesan; Pattabiraman, Nagarajan

PATENT ASSIGNEE(S): Nova Southeastern University, USA

SOURCE: U.S. Pat. Appl. Publ., 17pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080139585	A1	20080612	US 2007-859235	20070921
PRIORITY APPLN. INFO.:			US 2006-826390P	20060921

AB The invention describes isoindoles and derivs., aryl and heterocyclic compds., as well as pharmaceutically acceptable salt forms thereof, which are useful

10/576653

inhibitors of VEGFR. The compds. of the invention are useful in the treatment of cancer.

MSTR 1

G19-G13-G1

G1 = pyrimidinyl (opt. substd. by G2)
 G2 = (up to 3) G4
 G4 = 7 / CN

G5
 G5

G13 = 336-1 339-3

H3C-C(O)-CH2-C(O)

G19 = Ph (opt. substd. by (1-3) G20)
 Patent location: claim 1
 Note: substitution is restricted
 Note: additional ring formation also claimed
 Note: or pharmaceutically acceptable salts
 Stereochemistry: or stereoisomers

L36 ANSWER 5 OF 15 MARPAT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 147:257799 MARPAT Full-text
 TITLE: Preparation of (hetero)aryl ureas as cardiac sarcomere modulators for the treatment of heart failure
 INVENTOR(S): Morgan, Bradley P.; Muci, Alex; Kraynack, Erica; Tochimoto, Todd; Lu, Pu-Ping; Morgans, David J., Jr.
 PATENT ASSIGNEE(S): Cytokinetics, Inc., USA
 SOURCE: PCT Int. Appl., 93pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007089336	A2	20070809	WO 2006-US47668	20061214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,				

MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 20070197504 A1 20070823 US 2006-639398 20061213

EP 1959963 A2 20080827 EP 2006-849957 20061214


R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

PRIORITY APPLN. INFO.:

US 2005-750986P 20051215

WO 2006-US47668 20061214

GI



AB Title compds. I [wherein W, X, Y, Z = CH or N; T = bond, (un)substituted alkylene, O, etc.; R18, R19 = H, (un)substituted alkyl, heteroaryl, etc.; R1 = (un)substituted alkyl, amino, (hetero)aryl or (hetero)cycloalkyl; R2 = (un)substituted (hetero)aryl, (hetero)alkyl or (hetero)cycloalkyl; R3, R4, R5, R13 = H, halo, cyano, etc.; m = 1-3; R6, R7 = H, aminocarbonyl, alkoxy carbonyl, etc.; with limitations] and pharmaceutically acceptable salts, solvates, chelates, noncovalent complexes, prodrugs or mixts. thereof, which can selectively modulate the cardiac sarcomere such as by potentiating cardiac myosin, and therefore may be useful in the treatment of heart failure, were prepared For instance, successive EDC-mediated coupling of 4-chloro-3-cyanobenzoic acid with 1-(tert-butoxycarbonyl)piperazine, reduction of the resultant cyanobenzamide to a benzylamine, addition reaction with 3-isocyanato-6-methylpyridine, deprotection of the Boc group and reaction with mesyl chloride led to sulfonamide II.

MSTR 1

G1—G22—G19—G(0)—G17

10/576653

G1 = 67



G3 = CN

G10 = 160-3 164-68



G11 = NH2

G17 = 89



G18 = Ph (opt. substd.)

G19 = NH

G22 = CH2

G28 = NH

Patent location:

Note: substitution is restricted

Note: and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs and mixtures

Note: additional derivatization also claimed

L36 ANSWER 6 OF 15 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 147:9935 MARPAT Full-text

TITLE: Preparation of substituted 2-aminopyrimidines for treating or preventing A β -related pathologies
INVENTOR(S): Albert, Jeffrey; Chessari, Gianni; Edwards, Phil
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astex Therapeutics Ltd
SOURCE: PCT Int. Appl., 70pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007058581	A1	20070524	WO 2006-SE1281	20061113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,				


MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
 RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
 TZ, UA, BG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 EP 1951681 A1 20080806 EP 2006-813004 20061113
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
 IN 2008DN03799 A 20080815 IN 2008-DN3799 20080505
 PRIORITY APPLN. INFO.: US 2005-737435P 20051115
 WO 2006-SE1281 20061113

GI



AB Title compds. represented by the formula I [wherein Q = (un)substituted (hetero)cycloalkyl or (hetero)aryl; L = alkenylene, alkylene, alkylene, etc., R1 = H, (halo)alkyl, Si(alkyl)3, etc.; R2 = halo or OR3; R3 = (cyclo)alkyl, (hetero)aryl, aralkyl, etc.; and their pharmaceutically acceptable salts, tautomers or in vivo hydrolyzable precursors], useful for treatment or prophylaxis of A β related pathologies such as cognitive impairment, Alzheimer disease, neurodegeneration and dementia, were prepared For example, II+TFA was provided in a multi-step synthesis starting from 3-(3-bromophenyl)propionic acid. Compds. of the present invention have been shown to inhibit β secretase (including BACE) activity. Generally, the compds. of the present invention have been identified in one or both assays as having an IC50 of 100 μ M or less. Pharmaceutical compns. comprising compds. I, and methods of their use are disclosed.

MSTR 1



G1 = CN
 G11 = 85-4 88-81

g13-C(0)-G15-g13

G13 = G14
 G14 = (0-3) CH2 (opt. substd.)
 G15 = NH
 G18 = m-C6H4 (opt. substd.)

Patent location: claim 1

Note: or pharmaceutically acceptable salts, tautomers, or
 in-vivo hydrolyzable precursors

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 7 OF 15 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 145:167238 MARPAT Full-text

TITLE: Preparation of pyrazolopyridines for the treatment of
 diseases of dysregulated vascular growth

INVENTOR(S): Schwede, Wolfgang; Briem, Hans; Kuenzer, Hermann;
 Husemann, Manfred; Kettischau, Georg; Schaefer,
 Martina; Ter Laak, Antonius; Thierauch, Karl-Heinz;
 Ince, Stuart James

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: Eur. Pat. Appl., 46 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1683796	A1	20060726	EP 2005-75177	20050124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
WO 2006077168	A1	20060727	WO 2006-EP623	20060120
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1841767	A1	20071010	EP 2006-701504	20060120
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008528458	T	20080731	JP 2007-551638	20060120
US 20060252754	A1	20061109	US 2006-337114	20060123
			EP 2005-75177	20050124
			US 2005-64740/P	20050128
			WO 2006-EP623	20060120

PRIORITY APPLN. INFO.:



AB The title compds. I [R1 = alkyl, cycloalkyl, aryl, etc.; RA = H, (un)substituted alkyl; R2 = CONR7R77, SO2R7, CO2R7, etc.; R7, R77 = H, alkyl, cycloalkyl, etc.; Y1-Y5 = CH, CZ or N and N can stand from 0-3 times as a ring atom; Z = CN, NO2, halo, etc.; p = 0-4], useful for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compds. I effectively interfere with angiopoietin and therefore influence Tie2 signaling, were prepared E.g., a multi-step synthesis of II, starting from 4-aminobenzyl alc. and isocyanatobenzene, was given. Some of the exemplified compds. I such as II show high potency activity as inhibitors of Tie2 kinase and/or Tie2 autophosphorylation as measured with the ELISA method (IC50 values are below 5 μ M). Pharmaceutical compns. comprising the pyrazolopyridines I and method of preparing I were also disclosed.

MSTR 1



G2 = 35-6 33-25



G8 = 180

10/576653

~~1022-1029~~

G9 = N / 44

~~49~~—G10

G10 = CN / NH2

G17 = (1-4) CH2

G18 = NH

G19 = 149

~~149~~—NH—G25

G25 = Ph (opt. substd. by G26)

G29 = 67-13 68-152

~~6917-6818~~

Patent location: claim 1
Note: also incorporates claims 5 and 6
Note: substitution is restricted
Note: additional substitution also claimed
Note: and N-oxides, solvates, hydrates, isomers, and salts
Stereochemistry: and diastereomers and enantiomers
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
L36 ANSWER 8 OF 15 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 138:122653 MARPAT Full-text
TITLE: Pyrimidine derivatives for treatment of neurodegenerative diseases
INVENTOR(S): Fick, David B.; Foreman, Mark M.; Glasky, Alvin J.
PATENT ASSIGNEE(S): Neotherapeutics, Inc., USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003007963	A1	20030130	WO 2002-US23246	20020717
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG

US 20030055249	A1	20030320	US 2001-907273	20010717
AU 2002319634	A1	20030303	AU 2002-319634	20020717
US 20040116453	A1	20040617	US 2003-648046	20030825

PRIORITY APPLN. INFO.:

US 2001-907273	20010717
WO 2002-US23246	20020717

AB A pyrimidine derivative or analog comprises an amino-substituted six-membered heterocyclic moiety, moiety A, linked through a linker -L-C(O)- to a moiety B, where C(O)-B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y1)-D, where Y1 can be one of a variety of substituents, including H or alkyl, and D is a moiety that enhances the pharmacol. effects, promotes absorption, or promotes blood-brain barrier penetration of the derivative or analog. The moiety A can have two or three N atoms in the ring; typically, the moiety A is a pyrimidine moiety, with two N atoms in the ring. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biol. or physiol. activity. All cited compds. (e.g. 4-[[3-[(2-amino-6-chloropyrimidin-4-yl)amino]propionyl]amino]benzoic acid Et ester) have nootropic or anti-amnesic activity at doses of 10 mg/kg i.p. or less. Although the methods of preparation are not claimed, 3 example preps. are included.

MSTR 1

G1—G14—G21—C(O)—G24

G1 = 10




G13 = NH2
 G14 = NH
 G18 = 74

74—G19

G19 = CN
 G21 = G29
 G24 = 80

827-326

G26 = 99



G27 = NH
G29 = (1-6) CH2

Patent location: claim 1

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 9 OF 15 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 136:102370 MARPAT Full-text
TITLE: Preparation of tetrahydropyridine or piperidine heterocyclic derivatives and their affinity for CRF receptors
INVENTOR(S): Nakazato, Atsuro; Kumagai, Toshihito; Okubo, Taketoshi; Kameo, Kazuya
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002549	A1	20020110	WO 2001-JP5806	20010704
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2412287	A1	20020110	CA 2001-2412287	20010704
AU 2001069437	A	20020114	AU 2001-69437	20010704
EP 1299378	A1	20030409	EP 2001-947819	20010704
EP 1299378	B1	20070214		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
HU 2003001165	A2	20030828	HU 2003-1165	20010704
BR 2001012166	A	20030902	BR 2001-12166	20010704
JP 2004502685	T	20040129	JP 2002-507801	20010704
TW 591022	B	20040611	TW 2001-90116391	20010704
EE 200300007	A	20040816	EE 2003-7	20010704

10/576653

CN 1535968	A	20041013	CN 2004-10033876	20010704
AU 2001269437	B2	20051201	AU 2001-269437	20010704
AT 353885	T	20070315	AT 2001-947819	20010704
IN 2002KN01508	A	20040717	IN 2002-KN1508	20021210
ZA 2002010041	A	20031211	ZA 2002-10041	20021211
BG 107374	A	20040930	BG 2002-107374	20021211
NO 2002006125	A	20030204	NO 2002-6125	20021219
MX 2002PA12820	A	20030514	MX 2002-PA12820	20021219
US 20040034061	A1	20040219	US 2003-311277	20030825
US 6852732	B2	20050208		
HK 1057042	A1	20061013	HK 2003-109322	20031223
US 20050009874	A1	20050113	US 2004-912185	20040806
US 7160900	B2	20070109		

PRIORITY APPLN. INFO.:

JP 2000-204021	20000705
JP 2000-270535	20000906
WO 2000-JP5806	20000704
WO 2001-JP5806	20010704
US 2003-311277	20030825

AB Tetrahydropyridine or piperidine heterocyclic derivs. with high affinity for CRF receptors were prepared E.g., 5-(4-carbamoyl-1,2,3,6- tetrahydropyridin-1-yl)-2-(N-ethyl-2,4-dichloroanilino)-4-methylthiazole was prepared by bromination of 2-(N-ethyl-2,4-dichloroanilino)-4- methylthiazole hydrochloride, followed by reaction with 5-carbamoyl-1,2,3,6-tetrahydropyridine hydrochloride.

MSTR 1

G1—G11

G1 = 18



G3 = 33-2 33-19



G6 = 35




10/576653

G7 = 38



G8 = Ph

G11 = 165



G13 = 284



G15 = CN

Patent location:

claim 1

Note:

or pharmaceutically acceptable salts or hydrates

REFERENCE COUNT:

11

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 10 OF 15 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:

133:309900 MARPAT Full-text

TITLE:

Preparation of oxypyrimidinealkanoates and analogs as integrin receptor ligands

INVENTOR(S):

Zechel, Johann-Christian; Kling, Andreas; Geneste, Herve; Lange, Udo; Lauterbach, Arnulf; Graef, Claudia Isabella; Subkowski, Thomas; Sadowski, Jens; Hornberger, Wilfried

PATENT ASSIGNEE(S):

BASF Aktiengesellschaft, Germany

SOURCE:

PCT Int. Appl., 301 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061551	A2	20001019	WO 2000-EP2746	20000329
WO 2000061551	A3	20001228		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,

ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
 SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE 19916719	A1	20001019	DE 1999-19916719	19990413
DE 19962998	A1	20010712	DE 1999-19962998	19991224
CA 2368049	A1	20001019	CA 2000-2368049	20000329
AU 2000041129	A	20001114	AU 2000-41129	20000329
EP 1171435	A2	20020116	EP 2000-920612	20000329


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO

BR 2000009739	A	20020409	BR 2000-9739	20000329
TR 200102944	T2	20020821	TR 2001-2944	20000329
JP 2002541243	T	20021203	JP 2000-610827	20000329
JP 3936844	B2	20070627		
HU 2002003338	A2	20030328	HU 2002-3338	20000329
BG 105979	A	20020628	BG 2001-105979	20011004
MX 2001PA10232	A	20020327	MX 2001-PA10232	20011010
NO 2001004961	A	20011107	NO 2001-4961	20011012
US 7125883	B1	20061024	US 2002-958491	20020618

PRIORITY APPLN. INFO.:

DE 1999-19916719	19990413
DE 1999-19962998	19991224
WO 2000-EP2746	20000329

GI



AB BGUT [B = a structural element containing ≥ 1 atom capable of forming a H-bond under physiol. conditions (sic); G = (un)substituted divalent oxypyrimidine group I; T = CO₂H or a group hydrolyzable to CO₂H; U = bond, (heteroatom-interrupted) (oxo)alkylene, (hetero)arylene, etc.] were prepared as integrin receptor ligands (no data). Thus, ROCCH(NHCbz)CH₂NH₂ (R = resin) was cyclocondensed with R1CH:CMcCSNHCO₂Et (preparation given) to give a resin-bound oxothioxypyrimidine which was treated with BrCN and the product condensed with 1-(2-pyridinyl)piperidine-4-methanamine (preparation given) to give, after resin cleavage, title compound II.

MSTR 1B

530—51—510

10/576653

G1 = 34



G2 = 6-1 9-3 11-4 10-5



G3 = CN
G4 = NH (opt. substd.)
G30 = G31 / 230



G31 = 232



G32 = 375-2 376-231 / 377-2 378-231 / 379-2 381-231



G33 = O
G34 = 236



G35 = o-C6H4Me
G44 = NH (opt. substd.)
Patent location:
Note:

claim 1
additional ring formation and interruptions also


Note: claimed
and physiologically acceptable salts, prodrugs and
tautomers
Note: substitution is restricted
Stereochemistry: and enantiomers or diastereomers

L36 ANSWER 11 OF 15 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 127:331500 MARPAT Full-text
TITLE: New α -hydroxy acid derivatives as endothelin
receptor antagonists
INVENTOR(S): Klinge, Dagmar; Amberg, Wilhelm; Baumann, Ernst;
Kling, Andreas; Riechers, Hartmut; Unger, Liliane;
Raschack, Manfred; Hergenroeder, Stefan; Schult,
Sabine
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: Ger. Offen., 45 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19614533	A1	19971016	DE 1996-19614533	19960412
CA 2250757	A1	19971023	CA 1997-2250757	19970404
WO 9738981	A1	19971023	WO 1997-EP1688	19970404
W: AU, BG, BR, CA, CN, CZ, GE, HU, IL, JP, KR, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, BY, KG, KZ, MD, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9726365	A	19971107	AU 1997-26365	19970404
AU 731579	B2	20010405		
EP 892787	A1	19990127	EP 1997-918110	19970404
EP 892787	B1	20030611		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
CN 1222146	A	19990707	CN 1997-195488	19970404
BR 9708608	A	19990803	BR 1997-8608	19970404
HU 9901312	A2	19990830	HU 1999-1312	19970404
HU 9901312	A3	20000628		
NZ 332096	A	20000128	NZ 1997-332096	19970404
JP 2000508326	T	20000704	JP 1997-536699	19970404
AT 242770	T	20030615	AT 1997-918110	19970404
IN 1997MA00757	A	20050304	IN 1997-MA757	19970410
ZA 9703097	A	19981012	ZA 1997-3097	19970411
TW 425383	B	20010311	TW 1997-86104727	19970412
US 6686369	B1	20040203	US 1998-155944	19981008
NO 9804717	A	19981009	NO 1998-4717	19981009
NO 311801	B1	20020128		
KR 2000005369	A	20000125	KR 1998-708091	19981010
PRIORITY APPLN. INFO.:			DE 1996-19614533	19960412
			WO 1997-EP1688	19970404


OTHER SOURCE(S): CASREACT 127:331500
GI

10/576653



AB Title compds. I [R = CO₂H, CO₂Me, CN; R₁ = Me, Et; R₂ = Me, OMe] were prepared for use as endothelin receptor antagonists (no data). Thus, MeCPh₂CN was reductively hydrolyzed to MeCPh₂CHO which was treated with KCN to give MeCPh₂CH(OH)CN. This nitrile was hydrolyzed to the acid and treated with 4,6-dimethyl-2-chloropyrimidine to give I [R = CO₂H, R₁, R₂ = Me].

MSTR 1



G2 = 38



G14 = Ph (opt. substd.)

G15 = N

G17 = NH₂

G19 = 3




G21 = N

G24 = 80



G25 = CN


G31 = 106-82 105-7 106-83



Patent location: claim 1
 Note: substitution is restricted
 Note: additional ring formation also claimed

L36 ANSWER 12 OF 15 MARPAT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 126:330625 MARPAT Full-text
 TITLE: Preparation of (carboxymethylamino)heteroarenes as endothelin antagonists.
 INVENTOR(S): Klinge, Dagmar; Amberg, Wilhelm; Kling, Andreas; Riechers, Hartmut; Unger, Liliane; Raschack, Manfred
 PATENT ASSIGNEE(S): BASF A.-G., Germany
 SOURCE: Ger. Offen., 71 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19536891	A1	19970410	DE 1995-19536891	19951004
CA 2231500	A1	19970410	CA 1996-2231500	19960926
WO 9712878	A1	19970410	WO 1996-EP4205	19960926
W: AU, BG, BR, CA, CN, CZ, GE, HU, IL, JP, KR, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, BY, KG, KZ, MD, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9672147	A	19970428	AU 1996-72147	19960926
AU 713763	B2	19991209		
EP 874829	A1	19981104	EP 1996-933398	19960926
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI				
CN 1202890	A	19981223	CN 1996-198556	19960926
HU 9900085	A2	19990428	HU 1999-85	19960926
HU 9900085	A3	20011128		
BR 9610821	A	19990713	BR 1996-10821	19960926
JP 2000500738	T	20000125	JP 1997-513946	19960926
IL 123611	A	20010826	IL 1996-123611	19960926
ZA 9608304	A	19980403	ZA 1996-8304	19961003
IN 1996MA01755	A	20050304	IN 1996-MA1755	19961004
US 6440975	B1	20020827	US 1998-51020	19980331
BG 63389	B1	20011231	BG 1998-102362	19980401
NO 9801522	A	19980403	NO 1998-1522	19980403
NO 311025	B1	20011001		
PRIORITY APPLN. INFO.:			DE 1995-19536891	19951004
			WO 1996-EP4205	19960926
OTHER SOURCE(S): CASREACT 126:330625				
GI				


R⁶2CR⁴R⁵CR⁷NQR⁸

AB Title compds. [I; R = CHO, tetrazolyl, cyano, CO₂H, group hydrolyzable to CO₂H; R₂, R₃ = H, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, OH, SH, alkylthio, NO₂, amino, cyano, (substituted) Ph, heteroaryl; R₂X, R₃Y = atoms to form 5-6 membered (substituted) rings; W = N, CNO₂, CH; X = N, CR₁₅; Y, = N, CR₁₆; R₁₅, R₁₆ = H, alkyl, alkoxy, alkylthio, NO₂, Ph, OH, SH, halo, amino, cyano; R₄ = H, alkyl, cycloalkyl, (substituted) Ph, naphthyl, 5-6 membered heteroaryl; R₅ = alkyl, cycloalkyl, (substituted) Ph, naphthyl; R₆ = H, alkyl, haloalkyl; Q = bond, CO, CO₂; Z = bond, O, S, SO, SO₂; R₇ = H, alkyl, alkenyl, alkynyl, with provisos], were prepared as cardiovascular agents (no data). Thus, N-diphenylmethyleneglycine Me ester in THF was treated with LDA and then with di(3-methoxyphenyl)methyl bromide (preparation given) at -78° to give Me₂N- (diphenylmethylene)amino-3,3-di(3-methoxyphenyl)propionate. This was hydrolyzed to give 2-amino-3,3-di(3-methoxyphenyl)propionic acid, which was heated with 4,6-dimethoxy-2-methylsulfonylpyrimidine and Na₂CO₃ in DMF/H₂O to give 3,3-di(3-methoxyphenyl)-2-(4,6-dimethoxypyrimidin-2-yl)propionic acid.

MSTR 1A

G1—G2

G1 = 4



G2 = 5



G10 = Ph (opt. substd.)
 G11 = N
 G13 = NH₂
 G14 = N
 G16 = 69

10/576653



G17 = CN
G27 = 7



G28 = 41



Patent location:

claim 1

Note:

additional ring formation also claimed


Note:

substitution is restricted

MSTR 1B



G1 = 4



G2 = 5



G10 = Ph (opt. substd.)
G11 = N
G13 = NH2

10/576653

G14 = N
G16 = 69

69—G17

G17 = CN
G27 = 7

9(0)=28


G28 = 41

N
42 G10
G10

Patent location: claim 1
Note: additional ring formation also claimed
Note: substitution is restricted

L36 ANSWER 13 OF 15 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 124:288982 MARPAT Full-text
TITLE: Method for preparing alkylating agents and their use
for alkylating cyclic ureas
INVENTOR(S): Jadhav, Prabhakar Kondaji; Emmett, George Clautice;
Pierce, Michael Ernest
PATENT ASSIGNEE(S): Du Pont Merck Pharmaceutical Co., USA
SOURCE: PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9600708	A1	19960111	WO 1995-US8204	19950628
W: AU, CA, JP, MX, NZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5637780	A	19970610	US 1994-268610	19940630
AU 9529137	A	19960125	AU 1995-29137	19950628
AU 697035	B2	19980924		
EP 767770	A1	19970416	EP 1995-924750	19950628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 10502620	T	19980310	JP 1995-503442	19950628
PRIORITY APPLN. INFO.:			US 1994-268610	19940630
			US 1993-40146	19930330
			WO 1995-US8204	19950628
OTHER SOURCE(S):		CASREACT 124:288982		



AB The invention relates to methods for preparing alkylating agents and use of the prepared agents. In particular, it relates to preparation methods for hydroxy halide and organooxy halide alkylating agents, and their use for alkylating cyclic ureas in the preparation of HIV protease inhibitors. For example, partial chlorination of 1,4-benzenedimethanol with SOCl_2 in CHCl_3 at 0° to room temperature gave 75% 4-(HOCH_2) C_6H_4 (CH_2Cl). This chloro alc. reacted with Ph_3CCl and Ph_3COMe in PhMe and heptane, in the presence of a catalytic amount of 32% HCl , under reflux with partial distillation of solvent, to give 79% of the protected alkylating agent 4-(Ph_3COCH_2) C_6H_4 (CH_2Cl). This was used to alkylate the cyclic urea intermediate I [$\text{R}_1 = \text{R}_2 = \text{CH}_2\text{C}_6\text{H}_4$ (CH_2OCPh_3)-4; $\text{R}_3\text{R}_4 = \text{CMe}_2$] in 91% yield. This was deprotected with 32% HCl , in MeOH-PhMe , with NaOH workup, to give the desired product I [$\text{R}_1 = \text{R}_2 = \text{CH}_2\text{C}_6\text{H}_4$ (CH_2OH)-4; $\text{R}_3 = \text{R}_4 = \text{H}$], in 100% yield, on a 1.12-kg scale.

MSTR 1

G6—G8

G1 = (1-3) CH_2
 G6 = 12

12—G7

G7 = CONHPh
 G8 = 2 / 15

G2—G2—G1—G5 1 G1—G10


G10 = pyrimidinyl (substd. by 1 or more G11)
 G11 = (1) 45 / CN / NH_2

4 G1—G5

Patent location: claim 1

L36 ANSWER 14 OF 15 MARPAT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 125:35786 MARPAT Full-text
 TITLE: Reactive UV absorbers for stabilizing cellulosic
 fibers and increasing their sun protection factor
 INVENTOR(S): Fuso, Francesco; Reinert, Gerhard
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.; Ciba Specialty Chemicals
 Holding Inc.
 SOURCE: Eur. Pat. Appl., 29 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 707002	A1	19960417	EP 1995-810625	19951004
EP 707002	B1	20030326		
R: CH, DE, ES, FR, GB, IT, LI				
TW 383324	B	20000301	TW 1995-84109971	19950925
ES 2193181	T3	20031101	ES 1995-810625	19951004
BR 9504387	A	19970527	BR 1995-4387	19951011
US 5700295	A	19971223	US 1995-541007	19951011
AU 9534241	A	19960426	AU 1995-34241	19951012
AU 697581	B2	19981008		
ZA 9508595	A	19960515	ZA 1995-8595	19951012
CN 1125235	A	19960626	CN 1995-117292	19951012
CN 1075090	C	20011121		
JP 08193072	A	19960730	JP 1995-264455	19951012
JP 4067586	B2	20080326		
PRIORITY APPLN. INFO.:			CH 1994-3080	19941013
GI				




AB Comps. such as I are prepared and reacted with cellulosic fabrics to improve their resistance to photochem. degradation and enhance the protection of skin against UV radiation when the fabrics are used for clothing. Cyanuric chloride was reacted with N-(3-aminophenyl)-N'-(2-ethoxy-5-sulfophenyl)oxamide and H2N-p-C6H4SO2CH2CH2OSO3H to give I which was reacted with cotton fabric.

10/576653

MSTR 1



G1 = 21



G18 = 306-8 307-2 / 317-8 313-2



G20 = G52
G21 = O
G22 = NH
G23 = 328



G24 = CN
G25 = NH2 (opt. substd.)
G52 = (1-2) CH2

Patent location:

claim 1

Note:

substitution is restricted

L36 ANSWER 15 OF 15 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 122:216574 MARPAT Full-text

TITLE: Azo dyes, inks containing them, and recording method and instrument using the inks

INVENTOR(S): Eida, Tsuyoshi; Nishiwaki, Osamu; Yamamoto, Takaou; Mafune, Kumiko

PATENT ASSIGNEE(S): Canon K. K., Japan

SOURCE: Eur. Pat. Appl., 70 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 626428	A1	19941130	EP 1994-107608	19940517
EP 626428	B1	20001011		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 06329931	A	19941129	JP 1993-116075	19930518
JP 06329944	A	19941129	JP 1993-116076	19930518
JP 06329932	A	19941129	JP 1993-116185	19930518
JP 06329945	A	19941129	JP 1993-116186	19930518
US 5466282	A	19951114	US 1994-241592	19940512
AT 196917	T	20001015	AT 1994-107608	19940517
PRIORITY APPLN. INFO.:			JP 1993-116075	19930518
			JP 1993-116076	19930518
			JP 1993-116185	19930518
			JP 1993-116186	19930518

GI



I

AB The azo dye contains a structural unit XY(R1)(R2)(R3)k [R1 is N(CH2CH2OH)2, NHCH2CH2OH, amino acid residue; R2 is H, OH, NH2, CN, oxo, N(CH2CH2OH)2, NHCH2CH2OH, amino acid residue; R3 is H, OH, NH2, CN, oxo; X is a linking group; Y is a 6-membered ring containing 2-3 N; k = 0, 1]. Inks containing these dyes provide images with high optical d. and negligible feathering of dots, permit fast fixing, and are waterfast when used in copying on plain paper. Thus, 2,4-Me2C6H3NH2 was diazotized and coupled with H acid under alkaline conditions, and the product was condensed consecutively with cyanuric chloride and glycine to give I. An ink formulation comprised diethylene glycol 15, 2-pyrrolidinone 5, EtOH 3, I 3, and water 74 weight%, adjusted to pH 9.0-9.5.

MSTR 3


G1—22

G1 = 20


2411-2610

10/576653


G2 = 407



G10 = 24-21 27-2



G11 = 74



G13 = NH₂ / CN

Patent location:

claim 1

Note:

substitution is restricted

=> d his full

(FILE 'HOME' ENTERED AT 15:17:20 ON 01 OCT 2008)

FILE 'REGISTRY' ENTERED AT 15:17:27 ON 01 OCT 2008

```

L1      STRUCTURE UPLOADED
L2      7 SEA SSS SAM L1
L3      STRUCTURE UPLOADED
L4      7 SEA SSS SAM L3
        D SCA
        D STAT QUE L4
L5      STRUCTURE UPLOADED
L6      7 SEA SSS SAM L5
L7      196 SEA SSS FUL L5
        SAVE TEMP JAI653STR5L/A L7

```

FILE 'ZCAPLUS' ENTERED AT 15:39:52 ON 01 OCT 2008

```

L8      2 SEA ABB=ON PLU=ON L7

```

FILE 'BEILSTEIN' ENTERED AT 15:40:03 ON 01 OCT 2008

```

        D L5
L9      0 SEA SSS SAM L5
L10     0 SEA SSS FUL L5

```

FILE 'WPIX' ENTERED AT 15:40:39 ON 01 OCT 2008

```

L11     8 SEA SSS SAM L5
L12     49 SEA SSS FUL L5
L13     1 SEA ABB=ON PLU=ON L12/DCR
L14     STRUCTURE UPLOADED
L*** DEL 8 S L14

```

FILE 'MARPAT' ENTERED AT 15:43:35 ON 01 OCT 2008

```

L15     1 SEA SSS SAM L14
L16     15 SEA SSS FUL L14
L17     13 SEA ABB=ON PLU=ON L16/COM

```

FILE 'ZCAPLUS' ENTERED AT 15:47:24 ON 01 OCT 2008

```

L18     3072 SEA ABB=ON PLU=ON CHENG W?/AU
L19     20 SEA ABB=ON PLU=ON CO E?/AU
L20     19185 SEA ABB=ON PLU=ON KIM M?/AU
L21     2503 SEA ABB=ON PLU=ON KLEIN R?/AU
L22     3726 SEA ABB=ON PLU=ON LE D?/AU
L23     6 SEA ABB=ON PLU=ON TSUHAKE A?/AU
L24     149 SEA ABB=ON PLU=ON NUSS J?/AU
L25     9524 SEA ABB=ON PLU=ON XU W?/AU
L26     5 SEA ABB=ON PLU=ON L18 AND (L19 OR L20 OR L21 OR L22 OR L23
        OR L24 OR L25)
L27     8 SEA ABB=ON PLU=ON L19 AND (L20 OR L21 OR L22 OR L23 OR L24
        OR L25)
L28     16 SEA ABB=ON PLU=ON L20 AND (L21 OR L22 OR L23 OR L24 OR L25)
L29     5 SEA ABB=ON PLU=ON L21 AND (L22 OR L23 OR L24 OR L25)
L30     6 SEA ABB=ON PLU=ON L22 AND (L23 OR L24 OR L25)
L31     2 SEA ABB=ON PLU=ON L23 AND (L24 OR L25)
L32     13 SEA ABB=ON PLU=ON L24 AND L25
L33     24 SEA ABB=ON PLU=ON (L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR
        L32)

```

FILE 'MEDLINE, EMBASE, BIOSIS, WPIX' ENTERED AT 15:49:10 ON 01 OCT 2008

10/576653

L34 23 SEA ABB=ON PLU=ON L33

FILE 'REGISTRY' ENTERED AT 15:49:38 ON 01 OCT 2008

FILE 'ZCAPLUS' ENTERED AT 15:49:41 ON 01 OCT 2008
D STAT QUE L33

FILE 'MEDLINE, EMBASE, BIOSIS, WPIX' ENTERED AT 15:49:50 ON 01 OCT 2008
D STAT QUE L34

L35 FILE 'ZCAPLUS, MEDLINE, BIOSIS, WPIX' ENTERED AT 15:50:05 ON 01 OCT 2008
31 DUP REM L33 L34 (16 DUPLICATES REMOVED)
ANSWERS '1-24' FROM FILE ZCAPLUS
ANSWER '25' FROM FILE MEDLINE
ANSWER '26' FROM FILE BIOSIS
ANSWERS '27-31' FROM FILE WPIX
D IBIB ABS L35 1-24
D TALL L35 25-31

FILE 'REGISTRY' ENTERED AT 15:51:12 ON 01 OCT 2008

FILE 'ZCAPLUS' ENTERED AT 15:51:15 ON 01 OCT 2008
D STAT QUE L8

FILE 'BEILSTEIN' ENTERED AT 15:51:24 ON 01 OCT 2008
D STAT QUE L10

FILE 'WPIX' ENTERED AT 15:51:33 ON 01 OCT 2008
D STAT QUE L13

FILE 'MARPAT' ENTERED AT 15:51:40 ON 01 OCT 2008
D STAT QUE L17

L36 FILE 'ZCAPLUS, WPIX, MARPAT' ENTERED AT 15:52:01 ON 01 OCT 2008
15 DUP REM L8 L10 L13 L17 (1 DUPLICATE REMOVED)
ANSWERS '1-2' FROM FILE ZCAPLUS
ANSWERS '3-15' FROM FILE MARPAT
D IBIB ABS HITSTR L36 1-2
D IBIB ABS QHIT L36 3-15

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 SEP 2008 HIGHEST RN 1055704-91-0
DICTIONARY FILE UPDATES: 30 SEP 2008 HIGHEST RN 1055704-91-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information

on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

FILE ZCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 1 Oct 2008 VOL 149 ISS 14
FILE LAST UPDATED: 30 Sep 2008 (20080930/ED)

ZCaplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BEILSTEIN

FILE LAST UPDATED ON April 1, 2008

FILE COVERS 1771 TO 2008.

FILE CONTAINS 10.322,808 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For mo detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

```
*****
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *
*****
```

>>> Price change as of January 1st, 2008: Connect Time and Structure Search fees re-introduced. See NEWS and HELP COST <<<

FILE WPIX

FILE LAST UPDATED: 30 SEP 2008 <20080930/UP>

MOST RECENT UPDATE: 200862 <200862/DW>
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
 >>> Now containing more than 1.1 million chemical structures in DCR <<<
 >>> IPC Reform backfile reclassifications have been loaded to the end of
 June 2008. No update date (UP) has been created for the
 reclassified documents, but they can be identified by
 20060101/UPIC and 20061231/UPIC, 20070601/UPIC, 20071001/UPIC,
 20071130/UPIC, 20080401/UPIC and 20080701/UPIC.
 ECLA reclassifications to June and US national classifications to
 the end of April 2008 have also been loaded. Update dates
 20080401 and 20080701/UPEC and /UPNC have been assigned to these. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
 PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://scientific.thomsonreuters.com/support/patents/coverage/latestupdate>

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:
http://www.stn-international.com/archive/presentations/DWPIAnaVist2_0608.p

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

FILE MARPAT

FILE CONTENT: 1961-PRESENT VOL 149 ISS 12 (20080926/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
 (COVERAGE TO THESE DATES IS NOT COMPLETE):

US	20080194825	14	AUG	2008
DE	102007007185	14	AUG	2008
EP	1956050	13	AUG	2008
JP	2008182009	07	AUG	2008
WO	2008102086	28	AUG	2008
GB	2444641	11	JUN	2008
FR	2912404	15	AUG	2008
RU	2330029	27	JUL	2008
CA	2615024	14	JUN	2008

Expanded G-group definition display now available.

Effective December 15th the iteration and answer limits in MARPAT
 have increased from 100,000 to 200,000 for both on-line and batch
 searches. For more information on MARPAT search limits, type HELP
 SLIMITS at an arrow prompt.

FILE MEDLINE

FILE LAST UPDATED: 1 Oct 2008 (20081001/UP). FILE COVERS 1949 TO DATE.

MEDLINE has been updated with the National Library of Medicine's
 revised 2008 MeSH terms. See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate
 substance identification.

See HELP RANGE before carrying out any RANGE search.

MEDLINE Accession Numbers (ANs) for records from 1950-1977 have been converted from 8 to 10 digits. Searches using an 8 or 10 digit AN will retrieve the same record. The 10-digit ANs can be expanded, searched, and displayed in all records from 1949 to the present.

FILE EMBASE

FILE COVERS 1974 TO 1 Oct 2008 (20081001/ED)

EMBASE was reloaded on March 30, 2008.

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Beginning January 2008, Elsevier will no longer provide EMTREE codes as part of the EMTREE thesaurus in EMBASE. Please update your current-awareness alerts (SDIs) if they contain EMTREE codes.

For further assistance, please contact your local helpdesk.

FILE BIOSIS

FILE COVERS 1926 TO DATE.


CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT FROM JANUARY 1926 TO DATE.

RECORDS LAST ADDED: 24 September 2008 (20080924/ED)

BIOSIS has been augmented with 1.8 million archival records from 1926 through 1968. These records have been re-indexed to match current BIOSIS indexing.

Uploading L5.str

10/576653



0 = 1
s = 2
N = 3
C = 4

9 = 1
16 = 2
11 = 3
12 = 4

```
chain nodes :
7 8 22
ring nodes :
1 2 3 4 5 6 25 26 27 28 29 30
ring/chain nodes :
9 10 11 12 18 19 21 24
chain bonds :
2-7 5-8 21-22
ring/chain bonds :
6-18 18-19 19-21 21-24 24-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 25-26 25-30 26-27 27-28 28-29 29-30
exact/norm bonds :
1-2 1-6 2-3 2-7 3-4 4-5 5-6 5-8 6-18 18-19 19-21 21-22 21-24 24-27
25-26 25-30 26-27 27-28 28-29 29-30
```

G2:[*1],[*2],[*3],[*4]


G3:C,N

Connectivity :
7:1 E exact RC ring/chain 21:3 E exact RC ring/chain 22:1 E exact RC ring/chain

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 18:CLASS 19:CLASS 21:CLASS 22:CLASS 24:CLASS 25:Atom
26:Atom 27:Atom
28:Atom 29:Atom 30:Atom

10/576653

Uploading L14.str



0 * 1
S * 2
N * 3
C * 4

9 * 1
10 * 2
11 * 3
12 * 4

```
chain nodes :
7 8 22
ring nodes :
1 2 3 4 5 6 25 26 27 28 29 30
ring/chain nodes :
9 10 11 12 18 19 21 24
chain bonds :
2-7 5-8 6-18 18-19 19-21 21-22 21-24 24-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 25-26 25-30 26-27 27-28 28-29 29-30
exact/norm bonds :
1-2 1-6 2-3 2-7 3-4 4-5 5-6 5-8 6-18 18-19 19-21 21-22 21-24 24-27
25-26 25-30 26-27 27-28 28-29 29-30
```

G2:[*1],[*2],[*3],[*4]

G3:C,N

Connectivity :
7:1 E exact RC ring/chain 21:3 E exact RC ring/chain 22:1 E exact RC ring/chain

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 18:CLASS 19:CLASS 21:Atom 22:Atom 24:Atom 25:Atom 26:Atom
27:Atom 28:Atom
29:Atom 30:Atom

10/576653

=>